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Abstract 
 
Glioblastoma is the most common primary brain tumor in adults, and it is associated with 
a dismal prognosis with a median survival of 15 months. Despite treatment with chemotherapy, 
radiation therapy and surgery, patients inevitably have disease recurrence. Bevacizumab is a 
monoclonal humanized antibody that inhibits vascular endothelial growth factor signaling, and it 
has been shown to be effective in recurrent glioblastoma with respect to prolonging progression-
free  survival  (PFS).  The  use  of  bevacizumab  and  other  anti-angiogenic  agents  in  recurrent 
glioblastoma have created novel challenges in interpreting magnetic resonance imaging (MRI) of 
patients.  Furthermore,  since  only  some  patients  appear  to  have  a  durable  benefit  from 
bevacizumab, there is a need for imaging biomarkers that can reliably identify this subgroup of 
patients.  
Partly due to the challenges created by anti-angiogenic agents, the Response Assessment 
in Neuro-Oncology (RANO) was proposed to address some of the limitations with traditional 
response assessment criteria. In the first part of this project (Study 1), we attempted to validate 
the  RANO  criteria  by  performing  a  comparative  analysis  of  the  RANO  criteria  vs.  the 
Macdonald  criteria  using  imaging  from  the  phase  II  BRAIN  trial.  As  we  hypothesized,  the 
RANO criteria yielded a significantly decreased PFS by identifying a subset of patients who had 
progression of nonenhancing tumor evident on T2-weighted imaging. Additionally, response and 
progression as defined by the RANO criteria correlated with subsequent overall survival (OS) in 
landmark  analyses.  While  this  supports  the  implementation  of  RANO  criteria  for  response 
assessment in glioma clinical trials, future research will be necessary to further improve response 
assessment  by  incorporating  advanced  techniques  such  as  volumetric  anatomic  assessment, 
perfusion-weighted  MR  (PWI-MR),  diffusion-weighted  MR  (DWI-MR),  MR  spectroscopy 
(MRS) and positron emission tomography (PET).  3 
 
Advanced imaging techniques are becoming increasingly recognized for their ability to 
provide objective, non-invasive assessment of treatment response but also to serve as predictive 
and prognostic biomarkers allowing for stratification of patient subgroups with better treatment 
outcome. In the second part of the project, we attempted to perform volumetric analysis of tumor 
size  based  on  conventional  MRI,  as  well  as  a  histogram  analysis  of  apparent  diffusion 
coefficients (ADC) derived from diffusion-weighted MRI, to evaluate imaging parameters as 
predictors for PFS and OS in a single institution database of recurrent glioblastoma patients 
initiated  on  bevacizumab.  Volumetric  percentage  change  and  absolute  early  post-treatment 
volume (3-6 weeks after initiation) of enhancing tumor can stratify survival for patients with 
recurrent glioblastoma receiving bevacizumab therapy (Study 2
α). ADC histogram analysis using 
a multi-component curve-fitting technique within both enhancing and nonenhancing components 
of tumor prior to the initiation of bevacizumab can also be used to stratify OS in recurrent 
glioblastoma patients (Study 3
α). While prospective studies are necessary to validate findings, 
future studies will increasingly incorporate multiparametric approaches to elucidate biomarkers 
that combine the value of conventional MRI with advanced techniques such as DWI-MR, PWI-
MR, MRS and PET to obtain better predictors for PFS and OS in recurrent glioblastoma.  
 
αPublications resulting from the work described in this thesis 
The study described as Study 2 in this thesis has been published in Cancer. Reference: Huang 
RY
#, Rahman R
#, Hamdan A, et al. Recurrent glioblastoma: Volumetric assessment and 
stratification of patient survival with early posttreatment magnetic resonance imaging in patients 
treated with bevacizumab. Cancer. 2013. doi:10.1002/cncr.28210 [
#co-first authors]. 
A manuscript detailing Study 3 has been accepted for publication in the Journal of Neuro-
Oncology. Reference: Rahman R, Hamdan A, Zweifler R, Jiang H, Norden AD, Reardon DA, 
Mukundun S, Wen PY, Huang RY. ADC Histogram Analysis of Apparent Diffusion Coefficient 
within Enhancing and Nonenhancing Tumor Volumes in Recurrent Glioblastoma Patients 
Treated with Bevacizumab. Accepted for publication in the Journal of Neuro-Oncology. 
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Abbreviation Key 
VEGF: vascular endothelial growth factor 
RR: response rate (radiological) 
PFS-6: progression-free survival at 6 months 
OS: overall survival 
PFS: progression-free survival 
MRI: magnetic resonance imaging 
FLAIR or T2/FLAIR: fluid attenuated inversion recovery, T2-weighted 
RANO: Response Assessment in Neuro-Oncology 
RECIST: Response Evaluation Criteria in Solid Tumors 
MRS: magnetic resonance spectroscopy 
PWI-MR: perfusion-weighted magnetic resonance imaging 
PET: positron emission tomography 
DWI-MR: diffusion-weighted magnetic resonance imaging 
ADC: apparent diffusion coefficient 
fDM: functional diffusion map 
KPS: Karnofsky performance status score 
C-index: statistical parameter derived from concordance statistics 
T1+C: enhancing tumor component on T1-weighted imaging 
rNTR: ratio of nonenhancing tumor to enhancing tumor 
HR: hazard ratio 
ADCL: peak of low region of histogram with multi-component fitting, with ADC values < 1050 
x10
-6mm
2/sec 6 
 
ADCM: peak of middle two regions of histogram with multi-component fitting, composed of two 
components with fixed peak centers at 1150 x 10
-6mm
2/sec and 1350 x 10
-6mm
2/sec 
ADCH: peak of high region of histogram with multi-component fitting, center at 1550 x 10
-
6mm
2/sec 
IRF: independent radiology facility 
nCBV: normalized cerebral blood volume 
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Introduction to Recurrent Glioblastoma and Its Imaging 
Recurrent Glioblastoma: Background, Epidemiology, Treatment 
  Over 20,000 of primary brain tumors are diagnosed annually in adults in the US, and 
almost two-thirds of these tumors are high-grade gliomas.
1 Within this subset, over half are given 
the histopathological diagnosis of glioblastoma, which represents the most aggressive and most 
common primary brain tumor with an incidence of 3.2 per 100,000 in the United States.
2  
The current standard of care for newly diagnosed glioblastoma was established by a 
large, multi-institutional phase III trial that demonstrated the benefit of adding temozolomide to 
surgery and radiation.
3 Despite this advancement, glioblastomas are still associated with a dismal 
prognosis. The median survival for patients with newly diagnosed glioblastoma is 15 months.
4 
Given its aggressive, infiltrative nature, glioblastoma inevitably progresses through initial 
therapy. At the time of disease recurrence, there are limited options available for patients. For 
recurrent glioblastoma, the median progression-free survival is 9 months,
5 and the median 
survival of patients is 25 to 40 weeks.
6–8 
Prior to recent advances, the use of chemotherapeutic agents such as procarbazine and 
nitrosoureas were the standard of care for recurrent glioblastoma.
9,10 Based upon two recent 
phase III trials of nitrosourea monotherapy in recurrent glioblastoma,
11,12 these agents have been 
shown to have meager response rates (RR) of less than 10%. Single-agent irinotecan 
subsequently became a common agent to employ at recurrence of glioblastoma. With several 
phase II studies indicating a RR of less than 15%, this topoisomerase I inhibitor was also 
ineffective for the vast majority of patients.
13–15  
In light of recent advances in our understanding of the underlying molecular 
characteristics of glioblastoma, targeted therapy has been pursued to improve outcomes in the 
disease. Among its many pathologic hallmarks, glioblastoma has long been noted to have 8 
 
significant vascular proliferation with the increased expression of pro-angiogenic factors.
16 
Vascular endothelial growth factor (VEGF) is an important angiogenic factor that has been 
demonstrated to play an integral role in tumor angiogenesis.
17 Several anti-angiogenic agents 
targeting VEGF pathways have been successful in clinical trial for various human cancers.
18,19 In 
glioblastoma, VEGF has been demonstrated to be highly expressed, particularly in regions of 
tumor that are proximal to necrotic areas.
20–23 In fact, molecular studies have indicated that 
VEGF expression correlates well with both glioma grade and prognosis with higher VEGF 
expression associated with poorer prognosis.
24 Given the known role of VEGF in glioblastoma, 
studies in the late 1990s utilizing xenograft models of glioblastoma suggested that antibodies to 
VEGF could inhibit the growth and progression of the tumor.
25 
Bevacizumab (Avastin, Genentech) is a humanized monoclonal antibody that has its 
action against VEGF-A. As the first anti-angiogenesis agent approved for use in cancer, 
bevacizumab was initially demonstrated to be efficacious in metastatic colon cancer in a large 
phase III trial.
26 Subsequently, bevacizumab has been successfully used in metastatic non-small 
cell lung cancer and renal cancer.
27,28 With these successes and promising animal-studies work, 
bevacizumab was tested in patients with recurrent glioblastoma. A single-institution phase II 
study would demonstrate remarkable results with the use of bevacizumab and irinotecan, with a 
RR of 57% and a progression-free survival at 6 months (PFS-6) of 46% without excessive 
toxicity.
29 The promising results would be reproduced in the BRAIN trial, a multi-institutional, 
randomized, non-comparative phase II trial that examined the use of bevacizumab or the 
combination of bevacizumab with irinotecan in recurrent glioblastoma. In the BRAIN trial, 
published in 2009, patients exhibited a RR of 33% with a PFS-6 of over 40%.
5 These figures 
were a significant improvement over historical controls with systemic chemotherapies, which 
were estimated to be a RR of 5% and a PFS-6 of 15%.  9 
 
Based upon these dramatic results, bevacizumab received accelerated approval by the 
Food and Drug Administration for the treatment of recurrent glioblastoma in 2009.
30 Despite the 
hope provided by bevacizumab, several limitations of its use have been noted over recent years. 
First and foremost, over half of recurrent glioblastoma patients fail to respond to bevacizumab, 
which underlines the continued need for better therapies for this disease.
31 Furthermore, response 
to bevacizumab is often short-lived as patients inevitably develop resistance to therapy.  
The true benefit of bevacizumab remains unclear, especially because its ability to prolong 
overall survival (OS) is controversial. Compared to historical controls, it initially appeared that 
patients were receiving an OS benefit from bevacizumab.
5 A retrospective study would, 
however, subsequently suggest that anti-angiogenic agents do not prolong OS despite the 
dramatic effects on RR, PFS and PFS-6.
8 In fact, two large, phase III studies would support the 
notion that bevacizumab does not provide a survival benefit in glioblastoma, as both studies 
demonstrated known benefits in progression-free survival (PFS) without a subsequent benefit in 
survival.
32,33 The disparity between common clinical trial endpoints of RR, PFS and PFS-6 with 
OS raised awareness of the challenges in the neuro-imaging of glioblastoma, particularly in the 
setting of bevacizumab and other new anti-angiogenic agents.
34,35  
 
Imaging of Glioblastomas 
Prior to the advent of magnetic resonance imaging (MRI), computed tomography was the 
standard technique for the imaging of brain tumors. As early as 1981, MRI was noted to provide 
superior imaging of the brain parenchyma relative to computed tomography. 
36 Technology 
would rapidly develop as the introduction of both gadolinium-based contrast agents and high-
field scanners  in the early 1980s dramatically improved the ability to visualize the brain.
37,38 10 
 
With continued improvement of MRI technology, anatomic MRI represents the principle means 
of non-invasively assessing glioblastoma throughout its disease course.
39  
Conventional MRI protocols for brain tumors has traditionally included T1-weighted, 
post-gadolinium T1-weighted, and T2-weighted imaging. Fluid-attenuated inversion recovery 
(FLAIR) sequences represent strongly T2-weighted images with the suppression of signal in the 
cerebrospinal fluid, and this has become a part of standard imaging protocols since the late 
1990s.
39 Glioblastoma is classically characterized to be an intraparenchymal, heterogenously 
contrast-enhancing, bulky mass with areas of central necrosis.
40 Glioblastoma is known to have 
abnormal vasculature with a blood-brain barrier that is leaky and permissive of contrast 
extravasation, which results in its characteristic contrast enhancing appearance on post-
gadolinium images.
41  
The increased use of bevacizumab and other anti-VEGF agents have complicated the 
imaging of glioblastoma.
34 Bevacizumab causes a rapid decrease in the enhancement seen on 
MRI images of tumor, which is partly responsible for the high RR seen in clinical trials. Thus, 
the therapy actually alters the appearance of the tumor on MRI, but this does not necessarily 
represent anti-tumor activity of the drug.
42 This phenomenon has been termed pseudoresponse.
43 
The issue of pseudoresponse raises the concern that conventional MRI imaging of contrast-
enhancing tumor is an inadequate surrogate for actual tumor assessment. 
Furthermore, animal studies have revealed that tumors being treated with anti-VEGF 
agents may progress by overcoming the inhibition of angiogenesis by assuming a more 
infiltrative phenotype and siphoning off existing brain vessels.
44 Since this type of progression 
cannot be seen with post-contrast T1-weighted imaging, it has been termed non-enhancing 
progression. Non-enhancing progression can be visualized on T2-weighted and FLAIR images as 
increasing areas of hyperintensity.
45 The use of bevacizumab has been associated with an 11 
 
increasing incidence of nonenhancing progression that is apparent on T2/FLAIR imaging.
45 The 
lack of contrast enhancement has been suggested to represent the tumor’s evolution into a more 
diffuse, infiltrating phenotype that can be detected on T2/FLAIR without changes on T1-
weighted imaging.  
In the setting of bevacizumab, pseudoresponse and non-enhancing progression represent 
major considerations when interpreting MRI imaging of glioblastoma. The prediction and 
assessment of response to bevacizumab are an important challenge that have been difficult to 
address with traditional response assessment criteria.
46  
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Study 1: Validation of the RANO Criteria 
Given the emerging challenges in response assessments with neuro-imaging, clinical 
endpoints in glioblastoma have become an area of controversy in neuro-oncology.
47 Although 
overall survival (OS) is generally considered to be the “gold-standard endpoint”, the evaluation 
of therapy in phase II and III trials have historically also relied upon radiographic RR and PFS.
35 
In clinical trials of recurrent glioblastoma, RR and PFS are particularly important because these 
endpoints are not confounded by salvage therapies and other variables that may affect OS.
48,49 
Several studies utilizing clinical trial data have indicated that RR and PFS correlate with 
OS,
7,50,51 supporting their use as a reliable, efficient clinical endpoint in clinical trials.  
Since 1990, the main response criteria used in clinical trials in neuro-oncology has been 
the Macdonald Criteria, which uses two-dimensional contrast enhancing area to assess tumor 
size, in addition to corticosteroid use and clinical status.
52 It involves assessment of the contrast 
enhancing lesion on post-contrast T1-weighted imaging by measuring the longest axis multiplied 
by the longest perpendicular measurement in any plane. Response is defined as  >50% decrease 
in the bidimensional product. Progression is defined by >25% increase in the bidimensional 
product relative to the best response scan. Although it has been tremendously valuable for 
clinical trials, the Macdonald Criteria has a number of limitations in the setting of recurrent 
disease that have become increasingly problematic, especially due to phenomenon of 
pseudoresponse and nonenhancing tumor progression.
48,50  
To address several limitations of the Macdonald criteria, the Response Assessment in 
Neuro-Oncology (RANO) Working Group proposed newly updated response criteria for high-
grade gliomas in 2010.
53 They were designed to determine better criteria of response assessment 
that could enhance the interpretation of clinical trials in the setting of novel therapeutics such as 13 
 
angiogenesis inhibitors. The RANO criteria still uses two-dimensional contrast enhancing tumor 
as the basis of response, but it also accounts for T2/FLAIR nonenhancing tumor and provides 
guidelines on measurability, multifocal lesions, and pseudoprogression. The quantitative 
parameters for response and progression remain the same for contrast enhancing tumor. Of note, 
the RANO criteria did not specify quantitative thresholds for determining nonenhancing 
progression on T2/FLAIR imaging because of the difficulty in determining this by using 
standard two-dimensional measurements. Principles underlying the RANO criteria have been 
adopted into clinical trials involving high-grade gliomas, including the phase III AVAglio study, 
which was devised prior to publication of the RANO update.
46 Although a prior retrospective 
analysis comparing RANO, Macdonald and Response Evaluation Criteria in Solid Tumors 
(RECIST) indicated concordance among all of the one-dimensional and two-dimensional 
response assessment criteria among recurrent glioblastoma patients,
54 the RANO criteria has not 
yet been validated with outcomes data from a prospective trial.  
 
Study 1 Objective and Hypothesis 
In order to validate the RANO criteria as part of a multi-institutional effort, we analyzed 
the radiographic data of patients with recurrent glioblastoma being treated with bevacizumab or 
bevacizumab with irinotecan from the randomized phase II BRAIN trial
5 as a means to perform a 
comparative analysis of the Macdonald Criteria and the RANO Criteria with respect to RR and 
PFS. It was hypothesized that the RANO criteria would allow for a shorter PFS by identifying a 
subset of patients exhibiting nonenhancing progression. Further, we hypothesized that the 
surrogate endpoints of RR and PFS, as defined by the RANO criteria, would correlate with 
subsequent survival. Given the qualitative nature of determining nonenhancing progression per 14 
 
the RANO criteria, inter-observer variability was investigated among readers from different 
institutions and different specialty training (i.e. neuroradiologists and neuro-oncologists).  
 
Materials and Methods 
Patients  
All patients were from the phase II BRAIN trial,
5 which was performed to assess the 
effectiveness of bevacizumab with or without irinotecan in patients with recurrent glioblastoma. 
For this trial, 167 patients from multiple participating centers who had histologically confirmed 
glioblastoma at first or second relapse were enrolled. Disease progression that led to enrollment 
in the study was identified on MRI <14 days before the baseline treatment. These patients had 
failed the initial standard care plan including concurrent radiotherapy and temozolomide, and 
they were only enrolled if they were at least 8 weeks from the completion of radiation therapy. 
Bevacizumab was given at a dose of 10 mg/kg. The dose of irinotecan varied based on different 
clinical scenarios. All patients were treated for 104 weeks or until disease progression or 
discontinuation. Other inclusion criteria included Karnofsky performance status (KPS) >70 %; 
life expectancy >12 weeks; and adequate hematologic, hepatic, and renal function. Patients 
receiving corticosteroids were required to be on a stable or decreasing dose for at least 5 days 
before the baseline MRI scan. Of the 167 patients from the BRAIN study, 163 patients were used 
in the current analysis of PFS, based on the availability of both clinical data and pre-treatment T1 
post-contrast images and T2-weighted imaging of sufficient quality.  
All the images from the patients from the BRAIN study, including baseline MRI and 
follow-up MRIs performed every 6 weeks until progression or until the pre-determined clinical 
trial lock-date for imaging were obtained. Imaging and clinical data, including corticosteroid 15 
 
dosing, were acquired from Genentech. Data acquisition was performed in compliance with all 
applicable Health Insurance Portability and Accountability Act regulations (HIPAA).  
 
Radiological Response and Progression Assessment 
T1-weighted non-contrast and contrast-enhanced images and T2/FLAIR images were 
displayed on a picture archiving and communication system (PACS) workstation. For each 
patient, scans were read serially by a reader who was blinded to the number of scans available 
for each patient. The reader evaluated enhancing and nonenhancing tumor in order to determine 
response status and progression dates by Macdonald and RANO criteria. Only quantitative 
measurements of contrast enhancing tumor or new lesions qualified for progression by 
Macdonald criteria. Quantitative changes in T1-weighted gadolinium-enhancing lesion, as well 
as qualitative changes in non-enhancing T2/FLAIR, were used to assess treatment response and 
disease progression by RANO criteria. The dates of progression were determined by a radiologist 
blinded to clinical information. Once there was assignment of progression by RANO or 
Macdonald criteria, the reader was not able to modify the assigned progression date. Two-
dimensional measurements of contrast enhancing and nonenhancing tumor were recorded for 
every available scan. 
PFS and OS were calculated with respect to the date of bevacizumab initiation. 
Corticosteroid dosing was evaluated, and the PFS analysis was appropriately adjusted to account 
for increases in steroid dosing between imaging.  
 
Inter-observer variability 
All available scans of 163 patients were read and measured by a board certified neuro-
radiologist. The scans of 30 randomly selected patients were read by a board-certified neuro-16 
 
radiologist at a separate participating institution. The scans of 85 randomly selected patients were 
also read by board-certified neuro-oncologists in order to further assess variability.  
 
Statistical analysis 
Statistical analysis was completed by an outside institution in this collaborative multi-
institutional project. Kaplan-Meier estimates were used to calculate PFS and OS. Patients who 
did not progress were censored appropriately for the last scan date available. Patients who did 
not die were censored according to the last date known alive per the clinical data provided by 
Genentech. Correlative statistics were completed between PFS determined by the RANO and 
Macdonald criteria. The difference in PFS between RANO and Macdonald criteria was analyzed 
using log-rank testing. Response and progression were correlated to OS using landmark analyses 
at 2, 4 and 6 months with a Cox proportional hazards model implemented with response and 
progression treated as a time-dependent variable, respectively. Concordance statistics (C-index) 
was used to evaluate the predictive effects of PFS on OS with each respective criteria.  
Inter-observer variation was gauged with correlative statistics of the PFS and the absolute 
measurements of enhancing and nonenhancing lesions among readers.  
 
Results 
Patient characteristics  
Of the 167 patients (115 males) of the BRAIN trial, a total of 163 had available imaging. 
Patient characteristics, previously published,
5  are summarized in Table 1. Of note, the mean age 
was 56. A majority of patients (56%) had a KPS of 70-80, and 41% had a KPS score of 90-100. 
While 81% of patients were at first recurrence, 19% were at their second recurrence at time of 
enrollment into the clinical trial.   17 
 
 
Response: RANO vs. Macdonald 
For the response analysis, 156 of 167 patients had baseline and post-treatment imaging 
available for analysis. RR was 53.8% and 55.6% by Macdonald and RANO criteria, respectively. 
 
Correlating RR with overall survival 
Response as determined by Macdonald and RANO criteria were correlated with OS via 
landmark analysis completed at 2, 4, and 6 months (Figure 1).  
Landmark analysis using response as determined by Macdonald criteria indicated that 
response was predictive of OS at all time points after adjustment for appropriate clinical 
variables. At 2 months, responders had a HR 1.44 (95% CI: 1.01-2.04, p-value =0.0419) relative 
to non-responders. The C-index at 2 months was 0.547 (+/- 0.026). At 4 months, the HR was 
2.41 (95% CI: 1.61-3.59, p-value <0.0001) with a C-index of 0.618 (+/- 0.026).  At 6 months, the 
HR was 2.82 (95% CI: 1.72-4.63, p-value <0.0001) with a C-index of 0.612 (+/- 0.028).  
Landmark analysis using response as determined by RANO criteria indicated that 
response was also predictive of OS at all time points after adjustment for appropriate clinical 
variables. At 2 months, responders had a HR 1.48 (95% CI: 1.04-2.10, p-value=0.0274) relative 
to non-responders. The C-index at 2 months was 0.547 (+/- 0.026). At 4 months, the HR was 
2.12 (95% CI: 1.41-3.20, p-value =0.0003) with a C-index of 0.595 (+/- 0.026).  At 6 months, the 
HR was 2.11 (95% CI: 1.17-3.81, p-value=0.0128) with a C-index of 0.564 (+/- 0.024).    
 
Progression: RANO vs. Macdonald 
For the PFS analysis, 163 of 167 patients had an available treatment start date and were 
used for the analysis. Of 163, 86 patients had progressed per Macdonald criteria, and 111 18 
 
patients had progressed per RANO criteria. There were 37 patients who had a different 
progression date determined by RANO criteria relative to Macdonald criteria. Patients who did 
not progress were appropriately censored at last date of imaging without progression. Using 
Macdonald criteria, the median PFS was 5.52 months. By RANO criteria, the median PFS was 
4.21 months. Comparing the PFS resulting from the two criteria by log-rank test, the RANO 
criteria elicited a statistically significant decrease in PFS in comparison to the Macdonald criteria 
(Figure 2, p=0.0423).  
 
Correlating progression with overall survival 
Progression as determined by Macdonald and RANO criteria were correlated with OS via 
landmark analysis completed at 2, 4, and 6 months (Figure 3).  
Landmark analysis using progression as determined by Macdonald criteria indicated that 
progression was predictive of OS at all time points after adjustment for appropriate clinical 
variables. At 2 months, progressors had a HR 2.77 (95% CI: 1.56-4.92, p-value =0.0005) relative 
to non-progressors. The C-index at 2 months was 0.538 (+/- 0.013). At 4 months, the HR was 
3.53 (95% CI: 2.37-5.25, p-value <0.0001) with a C-index of 0.641 (+/- 0.022).  At 6 months, the 
HR was 3.67 (95% CI: 2.41-5.58, p-value <0.0001) with a C-index of 0.677 (+/- 0.027).  
Landmark analysis using progression as determined by RANO criteria indicated that 
progression was also predictive of OS at all time points after adjustment for appropriate clinical 
variables. At 2 months, progressors had a HR 3.19 (95% CI: 2.01-5.07, p-value<0.0001) relative 
to non-progressors. The C-index at 2 months was 0.578 (+/- 0.016). At 4 months, the HR was 
4.08 (95% CI: 2.75-6.07, p-value <0.0001) with a C-index of 0.667 (+/- 0.023).  At 6 months, the 
HR was 2.81 (95% CI: 1.85-4.26, p-value <0.0001) with a C-index of 0.675 (+/- 0.029).  
 19 
 
Inter-observer variability  
Inter-observer variability was assessed by comparing the primary reader vs. other readers 
(other institutions and/or other specialties). As indicated in Table 2, there was significant 
correlation between primary reader and other readers for PFS via Macdonald (r=0.689) and 
RANO (r=0.691) criteria. There was also significant correlation between primary reader and 
other readers regarding the change in absolute measurements for the contrast-enhancing lesion 
(r=0.623) and the nonenhancing lesion (r=0.544).  
After combining reads by everyone (n=278), there was significant correlation in PFS 
between Macdonald and RANO criteria (r=0.781).  
 
Discussion 
In this study, we compared the Macdonald and the RANO criteria using the radiological 
data from the phase II BRAIN trial of patients receiving bevacizumab or bevacizumab and 
irinotecan for recurrent glioblastoma. We furthermore examined the relationship of commonly 
used trial endpoints of RR and PFS, as determined by each criteria, with subsequent OS, which is 
the accepted gold-standard of clinical trial end points in glioblastoma. Although there was no 
significant difference in RR between the criteria, our results indicate that the use of RANO 
criteria was associated with a small difference in PFS that was statistically significant with a 
difference of 1.3 months in median PFS in comparison to the Macdonald criteria (p=0.0423, 
Figure 2). Furthermore, the endpoints of response and progression per RANO criteria, as well as 
Macdonald criteria, correlated with OS.   
 
Response Rate 20 
 
There were no significant differences in RR using Macdonald and RANO criteria. There 
were not many cases of patients who would exhibit a response on T1-weighted with contrast 
imaging who did not respond on the T2/FLAIR. Hence the study reproduced prior research in 
demonstrating that recurrent glioblastoma patients with a response while being treated with 
bevacizumab or bevacizumab with irinotecan have a longer survival compared to 
nonresponders.
50 Although a prior analysis of North Central Cancer Treatment Group clinical 
trials among recurrent glioblastoma patients did not elicit a statistically significant relationship 
between RR and OS,
87 there is a growing literature in recurrent glioblastoma patients initiated on 
bevacizumab that early response portends a better prognosis.
7,88 Our study further supports the 
notion that RR per RANO criteria can provide an early signal of anti-tumor activity and possibly 
an indication of durable benefit with anti-angiogenic agents.  
Of note, the RR determined by our independent reads are much greater than reported by 
the independent radiology facility (IRF; RadPharm, Inc.) in the published BRAIN trial.
5 These 
differences are likely attributable to several nuances of measurement delineated in the RANO 
criteria regarding assignment of response status. The RANO criteria provides a clear definition 
of measurable disease and its distinction from nonmeasurable disease, which was different from 
what was employed by the independent radiological reads in the BRAIN trial. The variability 
exhibited in our RR relative to IRF remains a reminder of the challenges and variability of 
imaging-based endpoints in the setting of anti-angiogenic therapies.  
 
Progression-free survival 
To our knowledge, this is the first study to indicate a statistically significant difference in 
PFS by using the RANO criteria in comparison to the Macdonald criteria. A prior, single-
institution study in recurrent glioblastoma patients on bevacizumab had indicated that the use of 21 
 
RANO trended towards a shorter PFS, but this did not reach statistical significance.
54 There were 
several differences between the Perez-Larraya et al. study and the present study that should be 
noted. The present study had a significantly larger sample (163 vs. 78) drawn from institutions 
across the country with strict trial inclusion criteria, which may allow for the detection of the 
modest improvement in PFS. Furthermore, the present study employed qualitative judgment of 
T2/FLAIR progression, as described by the RANO group. In contrast, Perez-Larraya et al. used 
quantitative measures to determine T2/FLAIR nonenhancing progression, which may increase 
objectivity but cannot detect subtle changes that can indicate nonenhancing progression at an 
earlier time point than two-dimensional measures. This difference in methodology may also 
explain the disparity in incidence of nonenhancing progression; the Perez-Larraya study 
identified 33% of patients exhibiting nonenhancing progression, while our analysis revealed 22% 
nonenhancing progression, which is more consistent with prior studies of T2/FLAIR 
nonenhancing, infiltrative progression.
85 The clinical relevance of the decrease in PFS is unclear. 
More importantly, there appears to be a subset of patients who demonstrate nonenhancing 
progression who benefit from being identified as progressors based upon T2/FLAIR signal. The 
RANO criteria appear to provide a clear benefit by identifying these patients as progressors so 
that clinicians and clinical trials can better approximate treatment failure.      
Progression determined by Macdonald and RANO were both predictive of overall 
survival. This finding would support the notion that the PFS determined by the RANO criteria 
represents a valid end-point even in the setting of anti-angiogenic therapies. The results are in 
agreement with prior studies that have demonstrated that progression determined by Macdonald 
and modified Macdonald criteria correlate with survival.
49,50,86 The benefit of using PFS as a 
clinical trial endpoint is its ability to evaluate the efficacy of a particular treatment without being 
confounded by salvage therapies.
35 As previously suggested by Han et al. in a meta-analysis of 22 
 
91 trials,
51 our study demonstrates that PFS determined by the RANO criteria remains a valid 
clinical trial endpoint in bevacizumab-treated patients. As PFS offers an opportunity for earlier 
outcomes assessment and higher statistical power at the time of analysis, our study supports its 
continued use as a surrogate endpoint of OS in recurrent glioblastoma clinical trials. 
By using concordance (C) statistics in the landmark analysis, we were able to better 
evaluate predictive effects of our progression co-variates on subsequent overall survival. The 
landmark analysis 2, 4, and 6 months using both criteria were significant at all time points for 
progression, with C-index ranging from 0.538 to 0.677. Interestingly, the C-index for 
progression trended towards increased values at later time points, and it was highest at 6 months 
(Macdonald 0.677, RANO 0.675). In other words, a patient’s progression status at 6 months was 
possibly more predictive of OS than progression status at an earlier time point. Although not 
directly tested, this would also support the use of progression-free survival at 6 months (PFS-6), 
which has been previously demonstrated by Lamborn et al. as a valid end point in trials for 
recurrent malignant glioma.
49 Of note, the C-index demonstrates modest predictive value of 
progression time points with Macdonald and RANO criteria. While this speaks to the value of 
using the RANO criteria to determine progression, developing better means of determining 
progression should allow for endpoints that are even more predictive of OS (C-index >0.7).  
 
Variability 
There was a significant correlation in PFS done by the primary reader and other readers 
using both the Macdonald (r=0.688) and RANO (r=0.692) criteria. This is primarily attributable 
to the fact that only a relatively small subset of patients in the recurrent setting exhibit 
nonenhancing T2/FLAIR progression and are therefore affected by the RANO criteria. The 
RANO criteria inherently has a greater degree of variability associated with it because of the 23 
 
subjective nature of determining nonenhancing, infiltrative progression. Among correlations of 
absolute measurements among readers, the correlation in the change of the nonenhancing lesion 
was lower in comparison to the correlation of measurements of the enhancing lesion. 
Quantifying infiltrative, nonenhancing tumor is challenging because there are several causes of 
increased T2/FLAIR abnormal signal including radiation effects, decreased steroid dosing, 
demyelination, ischemic injury, infection, seizures, and post-operative changes.
53 For this reason, 
the RANO Working Group did not provide an objective way to determine T2/FLAIR 
progression.
53 
Given the subjective nature of nonenhancing progression per RANO criteria, it is 
important to establish the predictive effects of PFS as determined by RANO on OS to exclude 
the possibility of excessive overestimation of progression. As illustrated in Figure 3, there does 
not appear to be excessive overestimation of T2/FLAIR, as there is still clear stratification of 
survival by landmark analysis of progressors vs. non-progressors at all time points.  
 
Study 1 Limitations 
There are several limitations that must be noted for this study. The BRAIN trial was a 
non-comparative phase II study in which all participants were treated with bevacizumab. There 
was no control arm and our conclusions cannot be applied to patients who do not receive 
bevacizumab. Furthermore, our time-to-event endpoints must be interpreted with caution given 
the retrospective nature of our analysis. While our studies support the use of RR and PFS as 
determined by the RANO criteria in clinical trials, larger prospectively designed studies are 
warranted. This is especially relevant because two recent large phase III clinical trials for newly 
diagnosed glioblastomas failed to demonstrate a survival benefit with the use of 
bevacizumab.
32,33 24 
 
Despite attempts to simulate real-life clinical decision making, the study was limited by 
its post-hoc design. Readers were blinded to clinical data as well as the total number of scans 
available for each patient. Hence, readers would have to decide upon progression without the 
knowledge of whether more scans were available, and this was implemented to reduce bias. 
Nonetheless, it was an experimental setting that failed to truly replicate clinical practice.  Reader 
fatigue may also have contributed since readers would serially go through many patients in a 
single sitting. Other limitations include the fact that imaging was only available up to 
progression or up to a pre-specified lock-date that was built into the trial design. Statistical 
analysis accounted for this by censoring appropriately based upon the available imaging 
 
Future Directions for Response Assessment 
As alluded to, the RANO criteria currently utilizes a qualitative approach to determining 
T2/FLAIR nonenhancing progression. There would be clear advantages to developing a reliable, 
quantitative means of identifying T2/FLAIR nonenhancing, infiltrative progression. The RANO 
criteria was developed with the intention of remaining open to modifications so that newer 
techniques can be incorporated in the future.  Ongoing research has been evaluating the potential 
use of advanced imaging in formal response assessment with promising preliminary results. 
While conventional linear measurements have been attempted to quantify changes in T2/FLAIR 
nonenhancing tumor,
85 advanced MRI techniques may be more helpful moving forward.  
One research area of great potential is the viability of volumetrics for assessing 
glioblastoma instead of traditional two-dimensional measurements.
60,88 Glioblastomas are 
notoriously difficult to measure due to their irregularity, which is only compounded by 
asymmetrical shape, necrosis, cystic areas, and treatment-related effects. Several studies have 
examined the use of volumetric approaches to response assessment in comparison to two-25 
 
dimensional measurements.
89,90  In a study of 104 patients with an enhancing glioma, Shah et al. 
demonstrated that one-dimensional, two-dimensional and volumetric measurements were 
comparable in determining progression.
89 These findings would be reproduced with the imaging 
from a large clinical trial dataset.
90 Of note, these studies were completed prior to the widespread 
adoption of anti-angiogenic agents, and they did not evaluate the use of volumetric analysis to 
quantify T2/FLAIR volume. At this point in time, volumetric approaches have not been 
sufficiently standardized nor validated in order to be seriously considered for incorporation into 
formal response assessment criteria. Nonetheless, they continue to be an important area of 
research that may play a role in response assessment in the future.   
Advanced MRI techniques such as DWI-MRI, PWI-MRI, and MRS, along with PET 
imaging, will require further study prior to consideration to become a standard part of response 
assessment. As subsequent studies delve into the use of advanced imaging in bevacizumab-
treated recurrent glioblastoma patients, further discussion is deferred. 
  Finally, measures of quality of life, neurocognitive function or steroid use have been 
discussed as possible clinical end points that may eventually be able to be incorporated into 
response assessment.
53 There are currently ongoing efforts to standardize neurologic assessment 
of high-grade glioma patients in order to provide a standardized tool to assess clinical status. If 
validated,
91 these are planned to be incorporated into the RANO criteria. 
 
Study 1 Conclusion 
The use of RANO criteria, in comparison to the Macdonald criteria, yields a shorter PFS 
because of its earlier identification of T2/FLAIR non-enhancing progressors. Response and 
progression determined by the RANO criteria were predictive of subsequent OS. Based upon 
these findings, it appears that RR and PFS determined by RANO criteria are reasonable end 26 
 
points for clinical trials of therapy in glioblastoma. The future development of quantitative 
approaches to evaluating T2/FLAIR nonenhancing progression will be helpful in reducing 
variability inherent in the RANO criteria.  
   27 
 
Prognostic and Predictive Imaging Biomarkers in Recurrent 
Glioblastoma 
Glioblastoma patient survival varies widely, and it is influenced strongly by patient age, 
performance status, completeness of resection and other factors.
55–57 While modern molecular 
diagnostics are exposing additional layers of genetic, epigenetic and other molecular variability 
underlying this striking phenotypic heterogeneity, prediction of treatment response and survival 
in individual patients remains a critical need. This need is particularly relevant in patients with 
recurrent glioblastoma where there appears to be a subset of patients who have a durable benefit 
from bevacizumab.  
Hence, in addition to assessing response and progression, evaluating predictive and 
prognostic biomarkers that can identify patients who are likely to be benefit from bevacizumab 
or other anti-angiogenic agents prior to or early in treatment would be tremendously helpful in 
order to better tailor therapy for patients and improve outcomes. With further analysis of 
conventional MRI and the development of MRI pulse sequences that are sensitive to physiology, 
new imaging-based biomarkers have been proposed for this purpose.  
In order to overcome limitations of conventional MRI, a wide range of advanced MR and 
metabolic imaging techniques have been introduced that examine prognostic and predictive 
imaging biomarkers including MR spectroscopy (MRS), perfusion-weighted MRI (PWI-MR), 
and metabolic positron emission tomography (PET) imaging.
58 While increasingly utilized in 
large academic centers, the most common imaging sequences that are widely implemented 
remain conventional MRI and diffusion-weighted MRI (DW-MRI).
39 Our studies focus upon the 
use of parameters derived from conventional MRI and DW-MRI, but several other advanced 28 
 
imaging techniques are being increasingly explored in bevacizumab-treated recurrent 
glioblastoma patients. It is worthwhile to review these methods.  
Perfusion imaging, PWI-MR, allows for routine non-invasive evaluation of tumor 
vascularity and angiogenesis, and it primarily uses  normalized cerebral blood volume (nCBV) as 
a marker for the presence of large dysplastic neovessels induced by VEGF and other vascular 
growth factors.
105,106 The relative amount of increased perfusion in gliomas has been correlated 
with tumor grade, as well as a prognostic marker for PFS and OS in newly diagnosed 
glioblastomas.
66,107–109 Sorensen et al. has described a “vascular normalization index” as a 
potential biomarker derived from PWI-MR that can predict response to a single dose of anti-
angiogenic therapy (cediranib) and predict for PFS and OS in recurrent glioblastoma patients.
110  
With increasing evidence in pilot studies that perfusion MR can be used as a predictor of 
bevacizumab response in recurrent glioblastoma,
111–113 a recent study by Schmainda et al. 
supported previous findings by demonstrating that PWI-MR can be used to predict response to 
bevacizumab while stratifying for PFS and OS in a single-institutional retrospective study of 36 
patients.
101  
MRI spectroscopy (MRS) provides valuable information about the tissue composition of 
tumor. Advanced methods have allowed for quantification of tumor metabolism markers 
including glucose, choline, creatine and N-acetyl-aspartate. While several studies have indicated 
great potential in utilizing MRS in the setting of anti-angiogenic agents, evidence for a role in 
better predicting and assessing response to bevacizumab therapy is sparser relative to other 
advanced MR techniques. In a small sample of 13 patients in a recurrent glioblastoma clinical 
trial, Ratai et al. demonstrated that changes in the ratio of N-acetylaspartate to creatine as early 
as 2 weeks after bevacizumab initiation was associated with antitumor effect.
102 Further research 
will be necessary to better establish the role of MRS in this treatment setting.  29 
 
PET imaging has been heavily studied in recurrent glioblastoma given its ability to 
provide information about metabolism and cell proliferation. The most commonly used 
radiotracer, 18-F-FDG can provide a surrogate for glucose uptake by cells, but high background 
uptake by the brain makes PET using this tracer difficult to interpret for glioblastoma. While a 
variety of tracers have been utilized, amino-acid based PET has been shown to be particularly 
useful as an imaging biomarker for predicting treatment response in brain tumors.
58 In a 
prospective pilot study of 21 recurrent glioblastoma patients treated with bevacizumab and 
irinotecan, Chen et al. indicated that PET imaging using 18-fluorothymidine (18-FLT-PET) as a 
tracer at 2 weeks and 6 weeks after bevacizumab initiation generated predictors of OS that was 
superior to responses elicited on conventional MRI.
100 Subsequent preclinical and clinical studies 
support the findings,
114,115 but larger studies are needed to better investigate the utility of PET 
imaging as an imaging biomarker in this setting. It must also be noted that PET imaging is 
particularly challenging because it is more costly and less widely available compared to MRI. In 
the absence of definitive evidence that PET imaging provides biomarkers with clear advantages 
over MRI, it will be difficult to incorporate this into routine clinical use for recurrent 
glioblastoma patients in the near future.  
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Study 2: Volumetric Assessment and Stratification of Patient 
Survival
 
Tumor volume assessed by a volumetric analysis on conventional MRI sequences 
represents a promising biomarker that has not been thoroughly explored in the literature.  While 
prior studies suggest that post-operative tumor volume and extent of resection have prognostic 
significance in newly diagnosed glioblastomas,
59,60 the importance of tumor volume in patients 
with recurrent tumor receiving anti-angiogenic therapy has not been extensively studied.  In 
patients with recurrent tumor receiving bevacizumab, results from a phase II clinical trial have 
shown that 4-week post-treatment response based on two-dimensional measurement correlates 
with PFS.
7  However, no studies to our knowledge have demonstrated the utility of using early 
post-treatment tumor volume and response for predicting PFS and OS.  
The use of three-dimensional volumes for recurrent glioblastomas is appealing because 
the tumors are challenging to measure with traditional two-dimensional methods. Glioblastomas 
classically exhibit irregular geometry, multifocality, and cystic or necrotic regions.  Volumetric 
methods have the advantage of more reproducibly and precisely measuring the size of tumor,
60–62 
which has led to an increasing interest of its utility in this context.  For example, volumetric 
measurement of both the enhancing and non-enhancing tumor have been investigated as imaging 
markers for treatment response,
45 PFS, and OS.
60,63  
 
Study 2 Objective and Hypothesis 
In order to examine volumetric analysis as a means of identifying patients likely to have a 
durable response to bevacizumab, we analyzed the radiographic data of patients with recurrent 
glioblastoma being treated with bevacizumab in an institutional database.  We assessed whether 31 
 
measurement of enhancing and nonenhancing tumor volume based on MRI at baseline and 3-6 
week post-treatment initiation are useful predictors for PFS and OS. It was hypothesized that 
tumor volume and percentage change of tumor volume would allow for stratification of patients 
for PFS and OS.  
 
Materials and Methods 
Patients 
The institutional review board approved this retrospective study with a waiver for 
informed consent.  Using a pharmacy database, we retrospectively identified 252 patients with 
pathologically confirmed glioblastoma (WHO IV) who received bevacizumab at our institution 
between December 2005 and July 2012 with recurrence based on clinical and imaging data.  
Recurrence was defined by new or increased size of enhancing tumor (>25% bidimensional 
products) based on MRI prior to bevacizumab initiation.  In order to be eligible, patients must 
have received bevacizumab with or without concurrent chemotherapy after failing no more than 
3 prior treatment regimens, including standard radiation and temozolomide therapy. They must 
have also undergone pre-treatment MRI within 2 weeks preceding bevacizumab initiation and a 
follow-up MRI 3 to 6 weeks after bevacizumab initiation.  Interpretable FLAIR, post-gadolinium 
T1-weighted, and DWI-MR sequences performed on either 1.5 Tesla or 3 Tesla MRI systems 
were also required at both imaging time points.  Using these screening criteria, a total of 91 
patients were selected. 
 
Disease Progression Assessment 32 
 
RANO criteria, including changes in T1-weighted gadolinium-enhancing lesions, as well 
as non-enhancing T2/FLAIR areas of abnormality, were used to assess disease progression.
53 
PFS and OS were calculated with respect to the date of bevacizumab therapy initiation. 
 
Enhancing and Nonenhancing Lesion Volume Segmentation 
Whole brain post-contrast T1 weighted and T2/FLAIR images from MRI obtained at 
baseline and after initiating bevacizumab were used for tumor volume segmentation.   All tumor 
segmentations were done using 3D Slicer Software (version 4.1, Boston, MA)
81,82 by an 
investigator who was blinded to clinical outcomes.  User-driven manual active contour 
segmentation was utilized to acquire volume quantification for the regions of interest in the 
enhancing tumor target(s) (T1+C) as well as T2/FLAIR abnormalities. Manual editing of tumor 
contour was also performed to exclude non-tumor regions such as areas of intrinsic T1 
shortening, necrosis, or surgical cavity.  Image volume was calculated by adding the number of 
pixels within volume contour and multiplying by pixel area and slice spacing. For multifocal 
tumors, the volume of separate lesions was summed together. Hence for each patient, a baseline 
and post-treatment enhancing and ‘T2/FLAIR’ volume was calculated. The percentage change in 
volume was calculated for both the enhancing and T2/FLAIR volume measurements for each 
patient. Also, the relative non-enhancing tumor ratio (rNTR), originally described by Norden et 
al. was calculated for both the baseline and post-treatment scans, respectively.
8  
 
Statistical analysis 
The primary outcome measures were PFS and OS. The Kaplan-Meier method was used 
to provide median point estimates and time specific rates. The Cox proportional hazards model 
was used in uni-variable and multi-variable settings to identify volumetric markers significantly 33 
 
associated with PFS and OS. Following analysis of clinical and volume parameters in this 
fashion, the sample was dichotomized by the median of the sample for each volume parameter. 
Appropriate subanalyses were planned to account for significant clinical variables found in the 
initial analyses. All of the statistical analyses were performed using STATA, version 12.0 
(College Station, TX).  
   
Results 
Patient clinical characteristics 
A total of 91 patients were selected using these screening criteria (51 males).  Among 11 
out of 91 patients who initiated bevacizumab within 12 weeks of the completion of concurrent 
chemoradiotherapy, tumor recurrence was supported by pathological confirmation on repeat 
resection (1 patient),  detection of new satellite lesion (1 patient), PET imaging (2 patients), or 
marked clinical deterioration (7 patients).  There were 12 patients with multifocal disease.  Forty-
seven patients were initiated on bevacizumab monotherapy, while 44 initiated bevacizumab with 
concurrent therapy. The concurrent therapies utilized in conjunction with bevacizumab included 
irinotecan (29 patients), temozolomide (6 patients), carboplatin (2 patients), carmustine or 
lumustine (4 patients), plerixafor (1 patient) and panobinostat (1 patient).  
At the time of initial diagnosis, all patients were treated with temozolomide and 
radiotherapy following maximal tumor resection. The mean age of patients was 56.3 years old 
(range 23-88). Of 91 total patients, 47 patients (51%) were initiated on bevacizumab on first 
recurrence, 29 (32%) on second recurrence, 11 (12%) on third recurrence and 4 (4%) on fourth 
recurrence. The baseline MRI was obtained a mean of 4.0 days (+/- 4.0) before bevacizumab 
initiation, and the follow-up MRI was obtained a mean 30.0 days (+/- 6.0) after bevacizumab 
initiation.  In terms of steroid usage, 51 patients were receiving dexamethasone (dose range 34 
 
0.25mg-24mg, median 4mg) at the time of the baseline imaging.  Forty-nine patients were 
receiving dexamethasone at time of immediate post-treatment scan (dose range 0.5mg-30mg, 
median 4mg). There were 16 patients who had an increased steroid dose at time of immediate 
post-treatment scan, while there were 49 and 26 patients with stable and decreased 
dexamethasone dosing, respectively. At the time of analysis, 70 patients died, and 85 patients 
had progressed per RANO criteria.
53  
The patient characteristics and baseline clinical variables with respect to PFS and OS are 
summarized in Table 3. Among clinical variables, number of recurrences and change in steroid 
dose from baseline to post-treatment scan were associated with PFS and OS. 
 
Univariable and multi-variable analyses of imaging parameters as continuous variables adjusted 
for clinical parameters. 
Age, number of recurrences, change in steroid dose, treatment regimen (bevacizumab 
monotherapy vs. concurrent chemotherapy) were included in a Cox proportional hazards model 
for evaluation with each imaging-based volumetric parameter (Table 4). Among radiologic 
variables, baseline enhancing volume, post-treatment enhancing volume, percent change, and 
post-treatment FLAIR volume were associated with OS.  Post-treatment enhancing volume and 
percent change of enhancing volume were also associated with PFS. The rNTR was not 
predictive of OS or PFS. In multi-variable analysis investigating baseline and post-treatment 
volume parameters, post-treatment enhancing volume remained significantly associated with OS 
and PFS while the baseline parameters did not (Table 5). 
 
Dichotomization of volumetric parameters using with sample median 
Enhancing volume parameters versus OS and PFS 35 
 
For each volume parameter, we dichotomized values by the sample median and then 
calculated Kaplan-Meier estimates of overall survival. The results for dichotomized enhancing 
volume parameters with hazard ratios (HR) from Cox proportional hazards model adjusted for 
age, use of steroids (yes or no), number of recurrences, and treatment regimen (bevacizumab 
monotherapy vs. bevacizumab with concurrent chemotherapies) are summarized in Table 6. 
When dichotomizing our sample by median baseline enhancing volume (19.46 cm
3), the baseline 
enhancing volume was predictive of OS (p=0.005) but not PFS (p=0.077, Figure 4A). When 
dichotomizing our sample by median post-treatment enhancing volume (7.8cm
3), the post-
treatment enhancing volume was predictive of OS (p<0.001), as well as PFS (p=0.018, Figure 
4B). When dichotomizing our sample using median percentage change in enhancing volume 
(52%), the percentage change was also predictive of OS and PFS (p=0.009 and p=0.001, 
respectively, Figure 4C). 
Since a 64% reduction in enhancing volume numerically extrapolates to a 50% reduction 
in two-dimensional bi-dimensional product and therefore is equivalent as a partial or complete 
response per RANO criteria,
53 we also examined this threshold in a similar analysis. 
Accordingly, patients with a greater than 64% reduction in enhancing volume also associated 
with longer OS and PFS (p=0.004 and p=0.024). 
 
T2/FLAIR volume parameters versus OS and PFS 
Baseline, post-treatment, and percentage change of T2/FLAIR volume was not predictive 
of OS or PFS when dichotomizing our sample by median value for each parameter (p>0.05).  
 
Combined stratifications using percentage volume change and residual enhancing tumor volume 36 
 
To examine the value of using both percentage volume change and residual enhancing 
volume, we first dichotomized the total patients group using 52% percentage change in 
enhancing volume, followed by dichotomization of each subgroup based on median residual 
enhancing volume of 7.8 cm
3. Kaplan-Meier estimates of overall survival were calculated for 
each of these groups (Figure 5). Based upon the Cox proportional hazards model, residual 
enhancing volume was still a significant predictor of OS within the subgroups of both responders 
and nonresponders, although not a predictor of PFS. Of these four groups, patients who were 
responders per enhancing volume reduction, defined as a > 52% response with a post-treatment 
enhancing volume of < 7.8cm
3 had the highest median overall survival, 70.3 weeks. The lowest 
median overall survival was of patients who were non-responders with a post-treatment volume 
of > 7.8cm
3, as the median overall survival for this group was 21.1 weeks.  
 
Subgroup analysis: Recurrences 
Since the number of recurrences was a significant predictor of overall survival in uni- and 
multi-variable analyses, we examined volume parameters in subsets of patients at 1st and 2nd 
recurrence, respectively.  
For patients at first recurrence (n=47), neither baseline enhancing volume nor percentage 
change were able to stratify the sample for survival using the previously listed median values for 
each parameter (p=0.294 and p=0.068, respectively). Dichotomization by post-treatment 
enhancing volume however, remained statistically significant (HR 1.98, p=0.044).  
For patients at second recurrence (n=29), neither baseline enhancing volume nor 
percentage change were able to stratify the sample for survival (p=0.168 and p=0.289, 
respectively). Dichotomization by post-treatment enhancing volume however, again remained 
statistically significant in patients (HR=2.83, p=0.035).  37 
 
 
Subgroup analysis: Bevacizumab monotherapy vs. bevacizumab with concurrent therapies 
In order to account for effects of heterogeneous concurrent therapies with bevacizumab 
given to some patients, we examined volume parameters among the subset of patients who 
received only bevacizumab monotherapy and those who received concurrent chemotherapy with 
Kaplan-Meier estimates.  For patients with bevacizumab monotherapy (n=47), baseline 
enhancing volume was not able to stratify the sample for survival (p=0.118). Patients with 
greater than 52% change or greater than 7.8cm
3 at post-treatment were associated with longer 
overall survival (p=0.024 and p<0.001, respectively) in this subset. 
  For patients with concurrent therapy in combination with bevacizumab (n=45), only 
baseline enhancing volume was able to stratify the sample for survival (HR 2.14, p=0.033). 
Neither percentage change of enhancing nor post-treatment enhancing volume parameters, 
dichotomized by median, were able to stratify by survival (p=0.177 and p=0.059, respectively). 
 
Discussion 
We assessed whether MRI-derived volume parameters prior to and early in treatment are 
useful predictors of outcome in patients with recurrent glioblastoma being initiated on 
bevacizumab.  Our results show that residual enhancing tumor volume and percentage change of 
enhancing tumor volume from baseline are both associated with PFS and OS.  Specifically, 
patients with residual enhancing tumor volume less than 7.8cm
3 have a longer median PFS (20.9 
weeks vs. 12.0 weeks) and OS (64.1 weeks vs. 27.7 weeks). Similarly, patients with >52% 
percentage reduction of enhancing volume on post-treatment scan compared to baseline also 
have a longer median PFS (20.9 weeks vs. 11.9 weeks) & OS (52.3 weeks vs. 31.0 weeks). Our 38 
 
results support the potential use of quantitative volumetric analysis early during bevacizumab to 
identify patients who may benefit more durably. 
Radiographic response has been previously shown to be a predictor of OS at 9, 18 and 26 
weeks using data from the phase II BRAIN Trial, although radiographic response was not a 
predictor of PFS in this study.
5,50 Another phase II trial of bevacizumab among heavily 
pretreated patients with recurrent glioblastoma indicated that early response at 4 weeks based on 
the Levin response assessment criteria is associated with a prolonged PFS. In this studyearly 
response based on objective Macdonald criteria did not demonstrate the same association.
7,92  
Our results indicate that the percentage of change at an early point in treatment may serve as a 
predictor for both PFS and OS. If one is to extrapolate the percentage change threshold from 2D 
to 3D, a 50% change in bidimensional products approximates a 64% change in volume. 
Consistent with two-dimensional studies, we demonstrated that percentage change in volume (< 
or > 64%) can also stratify patients with respect to PFS and OS. The robustness of our 
stratification may result from the advantages that come with a volumetric approach. By avoiding 
areas of necrosis, cysts and surgical cavity, volumetric segmentation may potentially estimate 
tumor size more accurately than linear methods.
27-29  
The same predictive significance of percentage change of enhancing tumor was not 
observed in a previous study using a volumetric approach.
63 As a distinguishing feature, our 
study included patients with a post-treatment MRI scan performed between 3 to 6 weeks; in 
contrast, the post-treatment scan was obtained after 6 to 8 weeks in the Ellingson et al. study. It 
is possible that the anti-permeability effect of bevacizumab may have a greater impact on the 
measurement of enhancing tumor volume when it is measured a later time point in therapy. If so, 
the percentage change in volume of enhancing lesion over a longer duration may less accurately 
reflect underlying tumor activity. Interestingly, in a different study by the same group which was 39 
 
subsequently completed, Ellingson et al. demonstrated results concordant with our own.
93 
Residual enhancing volume appears to be associated with PFS and OS, but it was not 
clear if this association was indirectly related to the percentage change in enhancing volume 
since these variables are interrelated. To investigate potential interactions between post-treatment 
and percentage volume change, we used residual enhancing volume (< or > 8 cm
3) to further 
stratify patients who had an early response (defined as > 52% reduction of enhancing volume) 
and patients without an early response. This created four subgroups from the original patient 
cohort (Figure 5).  There is a significant difference in median OS between the subgroups in 
pairwise comparisons.  The difference in PFS was not significant between the subgroups, 
possibly due to smaller sample size following combined stratifications.  These findings suggest 
that even if there is interaction between residual enhancing tumor volume and percentage volume 
change, the combined use of both parameters appears to further stratify patients with respect to 
OS. Specifically, patients with a response (> 52% reduction in enhancing volume from baseline) 
and small residual enhancing tumor volume (< 7.8 cm
3) had the longest median survival (70 
weeks).  On the other hand, nonresponding patients (<52% change in enhancing volume) and 
large post-treatment tumors (residual enhancing tumor volume > 7.8cm
3) had the shortest median 
survival (21 weeks).  Patients who were responders and yet still had large residual enhancing 
tumor and patients who were non-responders but small residual enhancing tumor had an 
intermediate median survival (28 weeks and 45 weeks, respectively).   
Given the current controversy about appropriate timing of bevacizumab treatment in 
patients with recurrent glioblastoma, it is important to assess volumetric parameters as a function 
of the number of recurrences to better clarify their contribution to overall outcome. As the 
number of recurrences was significantly associated with PFS and OS in univariable and 
multivariable settings, we conducted an analysis stratified by this variable. In the patient 40 
 
subgroup with one recurrence (n=47), residual enhancing tumor volume and percentage change 
in enhancing volume remained predictive of OS.  In patients with exactly two recurrences 
(n=29), only residual enhancing volume was predictive of OS, while percentage change was not. 
These parameters were also mostly not significant for PFS, which may be attributable to the 
relatively small sample size in each subgroup.  
The phenomenon of nonenhancing progression despite stable or improved enhancement 
following anti-angiogenic therapy, has led to the inclusion of consideration of the T2/FLAIR 
nonenhancing component of tumor in the RANO criteria as described in Study 1.  For this 
reason, we also assessed T2/FLAIR tumor size using volumetric analysis in this study.  While 
univariable analysis indicated that post-treatment T2/FLAIR volume correlated with PFS and 
OS, multivariable analysis indicated that T2/FLAIR is not significant following adjustment of 
clinical and other volumetric parameters. In this sample of heavily pre-treated patients, 
T2/FLAIR changes related to prior surgery, radiation and chemotherapy rather than underlying 
tumor activity may have contributed to measured T2/FLAIR volume as all abnormal signal was 
measured regardless of etiology.  
  Since the publication of our findings,
88 there have been several studies that have 
supported and enhanced our findings. Ellingson et al. have demonstrated that the use of 
subtraction maps of images that subtract intensity-normalized nonenhanced T1-weighted images 
from the contrast-enhanced T1-weighted images may allow for easier and more reliable 
volumetric segmentation of true enhancing tumor.
93 The study, utilizing the imaging from a 
multi-institutional clinical trial of bevacizumab-treated patients, confirms our findings that 
absolute residual volume and response can stratify for PFS and OS.  Furthermore, while we 
employed manual contouring of tumors, this represents a time-consuming technique that is open 
to inter-observer variability. There is increased evidence that newer semi-automated approaches 41 
 
are faster and more reproducible.
94 There has also been demonstration of improved ability to 
segment T2/FLAIR volumes specifically for nonenhancing tumor,
95,96 though the significance of 
this as a predictive biomarker is not clear.  
 
Study 2 Limitations 
First, as a retrospective analysis, our study findings will require prospective evaluation. 
In this study, we cannot determine whether the residual and percentage change of enhancing 
volume are predictive of prognostic because all patients in our cohort received bevacizumab.  To 
determine whether the volumetric imaging markers are specific to anti-angiogenic therapy, the 
same analysis should be investigated in recurrent glioblastoma patients treated without inhibitors 
of angiogenesis. In the absence of this comparison, the residual enhancing volume and 
percentage change of enhancing tumor volume cannot be definitively considered as predictors of 
bevacizumab therapy. Of note, while every patient in this study was initiated on a treatment 
regimen including bevacizumab, nearly half were also given concurrent chemotherapy.  
The MRI sequence used to assess tumor volume, as dictated by institutional protocols,had 
an inter-slice thickness of 5 mm, potentially introducing partial volume averaging during the 
tumor segmentation. While high-resolution 3D T1-weighted MR images would be expected to 
allow for a more precise volume measurement, a prior study indicated that performing 
volumetric analysis on traditional 2D imaging, as done in this study, leads to comparable 
measurements.
97 Nonetheless, if quantitative volumetric analysis is to be implemented clinically 
to inform clinical management, tumor volume measurement based on 3D source imaging will be 
preferred. With advances in imaging acquisition speed, 3D T1- and T2-weighted whole brain 
image sequences are increasingly acquired in both trial and clinical settings and will be helpful in 
allowing for more accurate volume measurements. 42 
 
 
Study 2 Conclusion 
We assessed baseline and early post-treatment volumetric parameters from T1-weighted 
and T2-weighted MRI imaging to evaluate their ability to predict PFS and OS in patients with 
recurrent glioblastoma being initiated on bevacizumab therapy. Volumetric percentage change 
and early post-treatment volume of enhancing tumor can stratify survival for patients with 
recurrent glioblastoma receiving bevacizumab therapy. T2/FLAIR abnormality volume was not 
able to stratify patients using this approach. Prospective validation of findings is warranted.  
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Study 3: ADC Histogram Analysis of Enhancing and Nonenhancing 
Tumor* 
The described study has been previously published in Cancer. 
DW-MRI examines tissue by probing water mobility to indirectly assess cell density and 
tissue architecture.  Given its relatively short acquisition time and high sensitivity to various 
brain pathology, this technique is commonly included as part of routine protocol for clinical 
imaging of brain tumors. The apparent diffusion coefficient (ADC) values derived from DW-
MRI are thought to be primarily determined by cell density; lower ADC values correspond to 
higher cell density, while higher ADC values occur in areas of edema and necrosis. ADC values 
of low-grade gliomas are often greater than those of the normal brain tissue but not significantly 
different from the ADC values of peritumoral edema.
64,65 In high-grade gliomas, however, lower 
ADC values are observed as a result of greater cellularity.
66 
Due to the regional variability commonly observed in gliomas including areas of 
necrosis, infiltrative tumor, edema and post-radiation change, it is difficult to exclude sampling 
bias when analysis is performed without taking the entire tumor volume into account. Thus, 
several recent studies have characterized diffusion imaging using volumetric segmentation 
methods in gliomas.
67–80  
These studies can be divided into those performing histogram analysis of diffusion data 
within the volume-of-interest from pretreatment MRI,
67,68,75,78,79 and those using a voxel-
subtraction functional diffusion map (fDM) technique tracking regional change between two 
different time points during the course of therapy.
70,73,74,80 Both techniques have demonstrated 
promising findings relating diffusion characteristics with treatment response and patient survival.   44 
 
Functional diffusion maps (fDMs), described in gliomas as early as 2005, are created by 
examining voxel-wise changes in ADC value.
76 ADC maps from specific time points in therapy 
are co-registered so that values can be compared over different time points. Prospective studies 
in newly diagnosed patients with high grade gliomas (anaplastic astrocytoma or glioblastoma) 
utilizing fDMs have demonstrated that greater increases in diffusion were exhibited in patients 
with a longer OS.
73 This finding has been extended to patients with recurrent glioblastoma being 
initiated on bevacizumab,
69 indicating that fDMs can be utilized to stratify patients for OS. 
Advances such as using graded fDMs, where the absolute change in ADC is taken into account, 
and non-linear registration of images are techniques that have demonstrated even greater 
sensitivity and specificity for predicting OS.
77  
As a more recently devised approach for glioblastoma, histogram analysis of ADC values 
has been utilized to stratify patients being initiated on bevacizumab for PFS.
67 Specifically, curve 
fitting with a double Gaussian model has been demonstrated to be effective as a imaging 
biomarker by dividing ADC values within tumor into a low ADC and high ADC peaks. These 
findings would subsequently be reproduced in a validation study that used a clinical trial imaging 
dataset by demonstrating that the pre-treatment ADC could stratify patients for OS.
78 Of 
particular interest, it appears that the use of pre-treatment ADC as a predictive biomarker is only 
applicable for recurrent glioblastoma patients being initiated on bevacizumab. Patients receiving 
an alternative systemic chemotherapy without an anti-angiogenic agent for recurrent 
glioblastoma could not be stratified with the pre-treatment ADC histogram analysis.
79  
While most prior analyses of diffusion imaging of high-grade gliomas focus on the 
volume of enhancement, there is evidence that characterization of ADC within the entire volume 
of T2/FLAIR abnormality can stratify patients in terms of survival.
70,71  Furthermore, to our 
knowledge, characterization of ADC histograms within the nonenhancing T2/FLAIR 45 
 
abnormality using multi-component curve-fitting has not been previously performed. It is unclear 
whether the analysis of the non-enhancing component of tumor can improve stratification of 
patient survival over analysis of enhancing tumor alone. 
 
Study 3 Objective and Hypothesis 
In order to examine the role ADC histogram analysis in the T2/FLAIR nonenhancing 
component of tumor as an imaging biomarker, we analyzed the radiographic data of patients with 
recurrent glioblastoma being treated with bevacizumab from an institutional database prior to 
therapy and early in treatment (3-6 weeks).  Based upon our prior study employing volumetrics, 
we hoped to apply examine the role of ADC histogram analysis within enhancing and 
nonenhancing tumor volumes. We hypothesized that parameters derived from multi-component 
curve-fitting of ADC histograms within nonenhancing T2/FLAIR abnormality can be combined 
with those derived from enhancing tumor to improve stratification of PFS and OS. 
 
Materials and Methods 
Patients 
The same single institutional database of recurrent glioblastoma patients being initiated 
on bevacizumab used in Study was analyzed in this study. As previously described, the 
institutional review board approved this retrospective study with a waiver for informed consent.  
Using a pharmacy database, we retrospectively identified 252 patients with pathologically 
confirmed glioblastoma (WHO IV) who received bevacizumab at our institution between 
December 2005 and July 2012 with recurrence based on clinical and imaging data.  Recurrence 
was defined by new or increased size of enhancing tumor (>25% bidimensional products) based 
on MRI prior to bevacizumab initiation.  In order to be eligible, patients must have received 46 
 
bevacizumab with or without concurrent chemotherapy after failing no more than 3 prior 
treatment regimens, including standard radiation and temozolomide therapy. They must have 
also undergone pre-treatment MRI within 2 weeks preceding bevacizumab initiation and a 
follow-up MRI 3 to 6 weeks after bevacizumab initiation.  Interpretable FLAIR, post-gadolinium 
T1-weighted, and DWI-MR sequences performed on either 1.5 Tesla or 3 Tesla MRI systems 
were also required at both imaging time points.  Using these screening criteria, a total of 91 
patients were selected. 
 
Disease Progression Assessment 
RANO criteria, including changes in T1-weighted gadolinium-enhancing lesions, as well 
as non-enhancing T2/FLAIR areas of abnormality, were used to assess disease progression.
53 
PFS and OS were calculated with respect to the date of bevacizumab therapy initiation. 
 
Enhancing and Nonenhancing Lesion Volume Segmentation 
As previously described for the volumetric assessment of Study 2, whole brain post-
contrast T1 weighted and T2/FLAIR images from MRI obtained at baseline and after initiating 
bevacizumab were used for tumor volume segmentation using 3D Slicer Software (version 4.1, 
Boston, MA)
81,82 by an investigator who was blinded to clinical outcomes.  In this study, the 
T2/FLAIR abnormality volume that overlapped with the enhancing lesion volume was subtracted 
so that the final T2/FLAIR volume only included the non-enhancing component of abnormality. 
 
Coregistration with ADC maps 
Prior to mapping the segmented enhancing and nonenhancing lesion volumes onto the 
ADC volume, the T1+C and T2/FLAIR whole brain volumes were spatially co-registered to the 47 
 
whole brain ADC volume using linear registration with affine transformation (12 degrees of 
freedom).  The ADC values of individual pixels within the T1+C and T2/FLAIR volumes were 
then plotted into histograms.  The schematic outline of volume segmentation and co-registration 
with ADC map is illustrated in Figure 6.  
 
Curve-fit analysis of Histogram of ADC volumes 
Curve-fitting and area integrations were performed using multiple Gaussian functions 
with peak center assignments based on previously reported ADC values of WHO grade III 
astrocytoma (1245 ± 153 x10
-6mm
2/sec) and glioblastoma (1079 ± 154 x10
-6mm
2/sec),
64 as well 
as peritumoral edema (1420 to 1825 x 10
-6mm
2/sec).
83,84 Due to overlapping ADC values 
between WHO grade III astrocytoma and glioblastoma, we defined pixels with ADC values 
lower than 1050 x10
-6mm
2/sec as the component of glioblastoma distinct from WHO grade III 
astrocytoma and assigned one Gaussian peak (ADCL) to fit this lowest ADC region in the ADC 
histogram. For the histogram component with ADC values greater than 1050 x 10
-6mm
2/sec, we 
used two separate Gaussian peaks (ADCM1 and ADCM2) using fixed peak centers at 1150 x 10
-
6mm
2/sec and 1350 x 10
-6mm
2/sec because the fitting appeared more reproducible compared to 
single broad peak assignment. We also assigned a fourth peak, ADCH, with a peak center at 1550 
x 10
-6mm
2/sec to account for peritumoral edema and regions of radiation leukoencephalopathy.  
In summary, the peak parameters were specified as the following: ADCL (center < 1050 x10
-
6mm
2/sec), ADCM (M1: center= 1150 x 10
-6mm
2/sec, width= 140, M2: center=1350 x 10
-
6mm
2/sec, width =140), ADCH (center = 1550 x 10
-6mm
2/sec) (Figure 7). The convergence 
criteria were determined by Levenberg–Marquardt algorithm. The peaks were area-integrated 
and expressed as ratios, including %ADCL (ADCL area / total Area), %ADCH (ADCH / total 48 
 
area), and ADCL  / ADCM (ADCL area / ADCM area). All curve fitting was done using Fityk 
(version 0.9.8, http://fityk.nieto.pl).  
 
Statistical analysis 
The primary outcome measures were PFS and OS. The Kaplan-Meier method was used 
to provide median point estimates and time specific rates. The Cox proportional hazards model 
was used in uni-variable and multi-variable settings to identify ADC imaging markers 
significantly associated with PFS and OS. Following analysis of clinical and ADC parameters, 
the sample was dichotomized by median values for each ADC parameter. Appropriate 
subanalyses were planned to account for significant clinical variables found in the initial 
analyses. All of the statistical analyses were performed using STATA, version 12.0 (College 
Station, TX).  
 
Results 
Patient characteristics 
The patient characteristics of this single institution database of patients have already been 
discussed in the Results section of Study 2. The patient characteristics and baseline clinical 
variables with respect to PFS and OS are summarized in Table 3. Among clinical variables, 
number of recurrences and change in steroid dose from baseline to post-treatment scan were 
associated with PFS and OS. 
 
Analysis of Imaging Parameters as Continuous Variables Adjusted for Clinical Parameters 
Each ADC parameter was first evaluated individually with clinical variables including 
age, gender, KPS, number of recurrences, baseline steroid dose, change in steroid dose, treatment 49 
 
regimen (bevacizumab monotherapy vs. concurrent chemotherapy), and re-resection before 
treatment in a Cox proportional hazards model (Table 6). Among the ADC variables, baseline 
%ADCH within T1+C, ADCL/ADCM within T2/FLAIR and post-treatment %ADCL within T1+C 
and ADCL/ADCM within T2/FLAIR were associated with both OS and PFS. None of the 
variables representing change in ADC parameters before and after treatment predicted PFS or 
OS.  
 
Multivariable analysis of dichotomized ADC parameters 
Subsequently, the four continuous ADC parameters with significant associations with OS 
(as well as PFS), specifically baseline %ADCH within T1+C, baseline ADCL/ADCM within 
T2/FLAIR, post-treatment %ADCL within T1+C, and post-treatment ADCL/ADCM within 
T2/FLAIR, were dichotomized by median values and were then included in multivariable models 
along with the same clinical variables and T1+C volume at baseline (Table 7).  Baseline volume 
parameters (enhancing tumor volume, %ADCH within T1+C < or > 25%, ADCL/ADCM within 
T2/FLAIR <= or > 0.64) were significantly associated with both OS and PFS.  The Kaplan-
Meier survival plots using %ADCH within T1+C, ADCL/ADCM within T2/FLAIR are shown in 
Figure 8A-D.  To account for both ADC parameters, we introduced a combined ADC factor, 
defined as %ADCH within T1+C divided by ADCL/ADCM within T2/FLAIR.  A cut-off of 0.8 
(n= 35 for factor > 0.8 and n= 56 for factor <= 0.8) was used for dichotomization of this factor 
after achieving the lowest hazard ratio for OS (Uni-variable: HR= 0.43, p =0.002; multi-variable 
adjusted for clinical variables: HR= 0.17, p < 0.0001) (Figure 8E and 8F). 
 
Stratifications of patient survival using baseline enhancing tumor volume and combined baseline 
ADC Factor 50 
 
To examine whether the combined baseline ADC factor can improve stratification of 
patient survival when assessed together with baseline volume of contrast enhancement, we first 
dichotomized the total patient group using the baseline T1+C volume of 20cc, followed by a 
second stratification using the combined baseline ADC factor with the aforementioned threshold 
of 0.8. Kaplan-Meier estimates of overall survival were calculated for each of these groups 
(Figure 9). Based on the Cox proportional hazards model, the ADC factor was still significantly 
associated with OS in both subgroups, among patients with baseline enhancing volume > 20cc 
(HR= 0.40, p = 0.017) and patients with baseline enhancing tumor ≤ 20cc (HR= 0.45, p= 0.039).  
Among these 4 groups, patients with smaller pretreatment volume, defined as ≤ 20cc, with a 
combined baseline ADC factor of > 0.8, had the longest median overall survival of 67.1 weeks. 
Patients with ADC factors of ≤ 0.8 and baseline volume > 20cc had the shortest median overall 
survival of 24.1 weeks. 
 
Subgroup Analysis: Recurrences 
Although the recurrences were not associated with overall survival in our multivariable 
analysis, it is important to test whether the ability of ADC parameters to stratify patient survival 
is affected by this variable. We examined ADC parameters in subsets of patients at first, second, 
and third recurrence (Table 8). For patients at first recurrence (n=47), both baseline %ADCH 
within T1+C and ADCL/ADCM within T2/FLAIR were able to stratify the sample for survival 
using the previously listed median values for each parameter (p = 0.037 and p < 0.0001, 
respectively). For patients at second and third recurrence with relative smaller sample size (n=29 
and 15, respectively), neither ADC parameter was able to stratify patients for survival.    
 
Subgroup Analysis: Bevacizumab monotherapy vs. bevacizumab with concurrent therapies  51 
 
In order to account for effects of heterogeneous concurrent therapies with bevacizumab, 
we examined the relationship of ADC parameters among the subset of patients who received 
only bevacizumab monotherapy and those who received concurrent chemotherapy with Kaplan-
Meier estimates. For patients with bevacizumab monotherapy (n = 47), both baseline %ADCH 
within T1+C and ADCL/ADCM within T2/FLAIR were able to stratify the sample for survival 
(p=0.07, p=0.013 respectively). For patients with concurrent therapy in combination with 
bevacizumab (n=44), neither ADC parameter was able to stratify the sample for survival (p=0.56 
and p=0.076, respectively). 
 
Discussion 
We analyzed the histogram of ADC maps from baseline and early post-treatment MRI 
exams in patients with recurrent glioblastoma treated with bevacizumab.  In addition to 
evaluating enhancing tumor volume on T1-weighted images, we also characterized 
nonenhancing volumes based on T2/FLAIR images and hypothesized that the ADC histogram 
analysis of the nonenhancing component of tumors can serve as an independent imaging 
biomarker.  Multi-component curve-fitting of T2/FLAIR abnormality at baseline MRI revealed a 
significant association between patient survival and the ratio of the ADCL peak to the ADCM 
peak.  These ADC values have been observed in glioblastoma and WHO grade III astrocytoma, 
with the lower peak (ADCL) reported in glioblastoma but not in WHO grade III astrocytoma.
64 
While the exact mechanism of our results is unclear, it is possible that patients with a greater 
ADCL / ADCM component had a greater proportion of volume within the non-enhancing 
T2/FLAIR abnormality behaving more aggressively or being more resistant to anti-angiogenic 
therapy.  Since the introduction of anti-angiogenic therapy, growth of non-enhancing infiltrative 
tumor has been recognized as a type of tumor,
45 and diffusion imaging has been shown to be able 52 
 
to detect nonenhancing tumor progression.
98 Our results provide evidence that the proportion of 
nonenhancing tumor likely contributing to unfavorable survival outcome can be assessed prior to 
treatment by analyzing ADC histograms within the T2/FLAIR abnormality.  The ability to assess 
this feature prior to initiating therapy makes it a particularly noteworthy finding.  
We also attempted to confirm the clinical significance of ADC histogram analysis within 
enhancing tumor on the baseline MRI as has been previously demonstrated in several studies.  
Rather than using a two-component curve-fitting analysis as done in prior studies,
67–69,78,79 we 
used a four-component curve-fitting algorithm. The inclusion of two additional peaks improved 
the accuracy and reproducibility of histogram fitting based on both visual inspection and residual 
function, and allowed for the identification of sub-components with ADC values corresponding 
to those observed in different histological grades of glioma.   Using this peak fitting algorithm, 
we observed that a greater percentage of the highest ADC peak area (%ADCH) is associated with 
longer PFS and OS.  This finding is concordant with prior two-component analysis of histogram 
that showed that a greater percentage of the lower ADC peak (or a smaller percentage of the 
higher ADC peak) in the bevacizumab treated group is predictive of shorter PFS.
78 In contrast to 
the analysis of the T2/FLAIR component, however, the ratio of ADCL to ADCM within T1+C 
was not associated with patient survival in our study (Table 6), indicating that the ratio between 
the ADCL and ADCM components of the enhancing volume is less important with respect to 
survival according to our results.  
A closer inspection of the Kaplan-Meier survival curve stratified by ADCL/ADCM within 
T2/FLAIR revealed that the separation of the curves is larger during the latter part of treatment 
course (Figure 8C), while the separation of survival curves stratified by %ADCH within the 
enhancing tumor is noticeable even at an early time point following treatment initiation (Figure 
8A).  Quantitatively, the 75
th percentile overall survival is 391 versus 695 days for ADCL/ADCM 53 
 
(T2/FLAIR) larger or smaller than 0.64. For %ADCH (T1+C) the 75
th percentile overall survival 
is 421 versus 568 days. Although speculative, these observations suggest that the subcomponents 
of nonenhancing tumor, while not necessarily helpful in identifying patients who progress very 
early following treatment, may identify patients who are long-term survivors following 
treatment. Further research will be required to investigate this hypothesis.  
In order to account for both the enhancing and nonenhancing components of tumor, we 
proposed a combined ADC factor, dividing %ADCH (T1+C) by ADCL/ADCM (T2/FLAIR). 
Using 0.8 as cut-off to stratify patients into groups with favorable and unfavorable ADC 
characteristics, the median OS was 224 vs. 455 days (p<0.002, HR=0.43) (Figure 8E).  The ratio 
of median OS in patient groups stratified by the combined ADC factor is 2.03, larger than either 
%ADCH within T1+C volume (1.3) or ADCL/ADCM within T2/FLAIR (1.86) alone.  
Furthermore, we have shown in our volumetric analysis of conventional MRI that the absolute 
tumor volume is an imaging marker correlating with patient survival. Using the combined ADC 
factor, we further stratified patient subgroups with different pretreatment volumes (> or <= 
20cc), resulting in significant differences in both OS and PFS for both volume groups (Figure 9). 
This represents a method to combine volumetric approach with ADC histogram to demonstrate 
that they are both individually helpful in stratifying patients.  
There has now been a significant amount of research demonstrating the possible benefits 
of ADC histogram analysis of the baseline scan prior to initiating bevacizumab. In this single 
institution study, all patients received bevacizumab and there was no comparative arm. While 
ADC histogram analysis appears to be an imaging biomarker that can stratify for PFS and OS, 
our study was unable to determine whether this serves a predictor to bevacizumab therapy or if it 
is simply a prognostic marker independent of therapy. Ellingson et al. (2013) has recently 
demonstrated that the baseline ADC histogram analysis does not stratify recurrent glioblastoma 54 
 
patients for PFS or OS in patients who are receiving systemic chemotherapy (and not 
bevacizumab).
79  If corroborated, this would indicate that ADC histogram analysis may have the 
potential to be used to identify patients who are most likely to achieve a durable benefit from 
bevacizumab. Given that most other imaging biomarkers that are being evaluated as predictors of 
response in bevacizumab involve early post-treatment imaging,
73,74,100–102 the use of ADC 
histogram analysis requires further investigation with respect to its ability to identify patients 
likely to receive a durable benefit from bevacizumab prior to treatment initiation.  
Assessment of ADC histograms from early (3-6 week) post-treatment MRI may also 
provide useful prognostic information immediately following the first few doses of treatment.  
While several post-treatment ADC parameters appear to be associated with PFS and OS (Table 
6), the associations were not significant in multi-variable analysis when assessed with 
pretreatment ADC parameters and clinical variables (Table 7).  A number of possibilities can 
contribute to the component of low ADC lesions following anti-angiogenic therapy.  For 
example, prior studies have shown that low ADC lesions can be seen following treatment and 
represent chronic hypoxia and atypical gelatinous necrotic tissue.
98,103 In addition, areas of prior 
edema can normalize, and the ADC value may approach that of normal white matter, which is 
also in the range overlapping with high grade glioma.
65 To better characterize the diffusion 
properties of tumor following treatment, further decomposition of the ADCL peak may be 
helpful.  High b-value diffusion is a promising technique that potentially can better characterize 
the ADCL peak as evidenced by prior studies.
104 With the techniques used in this study, however, 
post-treatment ADC parameters did not appear to be as helpful as baseline imaging parameters.  
The change of ADC parameters before and after treatment initiation also did not correlate 
with survival.  ADC parameters were ratios of peak areas and there is often significant difference 
between volumes before and after treatment, and direct subtraction likely does not represent the 55 
 
actual volume change of a particular sub-peak.   Even if adjusted for volume, the location 
information is lost during analysis.  The voxel-subtraction method of fDM, however, has the 
advantage of assessing change in ADC within all regions of tumor or adjacent brain, thus should 
be more accurate in reflecting treatment-related effect.  Several prior studies have demonstrated 
the value of this method in correlating serial ADC change to survival.
70,71 It is worth noting that 
the parameters from histogram analysis of pretreatment MRI and fDM analysis of serial MR 
imaging can be complementary and used together in the future.  
 
Study 3 Limitations 
First and foremost, as with the other parts of this project, the findings from our 
retrospective study need to be confirmed in future prospective trials.  As previously alluded to, 
there was no control group that did not receive anti-angiogenic therapy, thus not allowing for 
confirming the prognostic or predictive nature of the ADC parameters with respect to patient 
survival outcome. While others have supported the notion that the pre-treatment parameters from 
ADC histogram analysis can serve as a predictor of response specific for bevacizumab therapy,
79 
we were unable to investigate this.  Nearly half of our patients received one or more concurrent 
chemotherapies in addition to bevacizumab, making it more difficult to draw conclusions 
regarding treatment-specific benefits of our approach.  Nonetheless, subgroup analysis of 
patients who only received bevacizumab monotherapy indicated that the association of ADC 
parameters remains significant with respect to OS. Furthermore, the number of recurrences 
included in our patient selection criteria is not uniform, ranging between 1 and 3.   Interestingly, 
the significant association of ADC parameters with patient survival was observed only in the 
group with one recurrence in our subanalyses, again suggesting that alterations of ADC 56 
 
characteristics due to successive treatment regimens may confound histogram analysis that is 
based on previously established ADC values of untreated tumor.   
As with Study 2, the distinction of pseudoprogression and early recurrence is important 
because its misclassification can affect outcome assessment.  As already described, several 
measures were taken to minimize the possible impact of pseudoprogression.  
While our multi-component approach to ADC histogram approach allowed for greater 
decomposition of enhancing and nonenhancing tumor, it is not clear if this is a better approach 
then the more commonly employed bi-component analysis. We utilized a four-component model 
because of better visual fit and improved residual function, but a comparative study would be 
needed to better evaluate this question. Furthermore, pathological correlates via prospective 
studies involving biopsy of areas corresponding to different peaks of ADC histograms would be 
the gold standard for validating our interpretation of our multi-component curve fitting 
technique.  
 
Future Direction for Prognostic/Predictive Imaging Biomarker Research 
The results from the volumetric and ADC histogram study add to a growing body of 
knowledge regarding imaging biomarkers in recurrent glioblastoma. Several barriers remain 
prior to implementation of these imaging biomarkers in everyday clinical use. First, there is a 
great degree of heterogeneity with respect to exact parameters used to acquire MRI imaging at 
centers around the country and world. The cutoff values presented in this project represent the 
results from a single institution experience that cannot be necessarily generalized to the broader 
glioblastoma population. Standardization of methods is logistically challenging but would 
represent an important step towards allowing for better evaluation of research and facilitating 
eventual acceptance of specific cutoff values used for volumetric and ADC parameters. 57 
 
Furthermore, large multi-institutional, prospective studies are needed to verify the importance of 
volumetric segmentation and ADC histogram analysis in recurrent glioblastoma patients being 
initiated on bevacizumab. Hence, future research should be aimed at validating findings that 
have accumulated in support of volumetric analysis and ADC histogram analysis as imaging 
biomarkers in bevacizumab-treated recurrent glioblastoma patients.  
With so many advanced imaging techniques in development, each one has become 
increasingly recognized to be valuable in terms of characterizing different pathophysiological 
aspects of tumor and treatment changes in the setting of inhibitors of angiogenesis. While 
individually helpful, the combination of these techniques represent a promising way of creating 
powerful imaging biomarkers and metrics that may better predict and assess response to therapy. 
In our ADC histogram analysis study, we demonstrated that absolute volume and baseline ADC 
parameters can be utilized together to allow for stratification of patient groups by survival 
(Figure 9). More sophisticated means of utilizing the information from different techniques can 
offer more powerful stratifications. Multiparametic approaches have been utilized in high-grade 
gliomas for other purposes (e.g. differentiating recurrence from radiation necrosis),
116 and future 
research should explore their ability to be generate imaging biomarkers in recurrent glioblastoma 
patients being initiated on bevacizumab.  
 
Study 3 Conclusion  
We assessed several ADC parameters derived from histogram analysis of contrast-
enhancing and T2/FLAIR nonenhancing areas of tumor in patients with recurrent glioblastoma 
being initiated on bevacizumab therapy. Our analysis indicates that ADC histogram analysis 
within both enhancing and nonenhancing components of tumor may be used in combination to 
stratify patients with respect to PFS and OS. 58 
 
 
Summary 
  The overarching theme of the project was to examine the utilization of MRI in recurrent 
glioblastoma with respect to response assessment and as imaging biomarkers that may have a 
prognostic or predictive role. In Study 1, our goal was to validate the RANO criteria for response 
assessment in recurrent glioblastoma by performing a comparative analysis with the Macdonald 
criteria. In the second part of the project, our goal was to evaluate imaging biomarkers derived 
from (a) volumetric analysis of conventional MRI (Study 2) and (b) histogram analysis of DWI-
MR of both enhancing and nonenhancing tumor (Study 3) in their ability to stratify patients for 
PFS and OS.  
Taken together, we believe that the results of our project provide important advances in 
the  imaging  of  recurrent  glioblastoma.  Given  the  need  for  better  therapeutics  for  recurrent 
glioblastoma  because  of  its  dismal  prognosis,  clinical  trials  are  essential  for  discovering 
improved  therapeutics,  and  response  assessment  represents  a  critical  aspect  of  treatment 
evaluation.  Based  upon  improvements  relative  to  the  Macdonald  criteria,  the  RANO  criteria 
provides  several  advantages  in  better  determining  response  and  progression  for  therapies, 
particularly in the setting of new anti-angiogenic agents. By using outcomes and imaging from a 
phase II clinical trial of bevacizumab in recurrent glioblastoma, we have demonstrated that the 
RANO  criteria  improves  determination  of  progression  through  its  consideration  for 
nonenhancing tumor apparent on T2/FLAIR imaging. As the imaging endpoints determined by 
the RANO criteria correlate with subsequent survival, our results support the use of RANO in 
clinical trials of high grade gliomas.   59 
 
Despite the progress represented by the RANO criteria, the advent of advanced imaging 
techniques has the potential of better identifying patients likely to benefit from certain therapies 
and to serve as biomarkers with prognostic or predictive significance. A volumetric assessment 
of enhancing tumor prior to and early in treatment appears to be beneficial in both identifying 
patients  more  likely  to  achieve  a  durable  response  with  bevacizumab.  Similarly,  our  work 
supports  the  potential  use  of  ADC  histogram  analysis  of  both  enhancing  and  nonenhancing 
components of tumor as a predictive imaging biomarker to identify patients who are likely to 
benefit from bevacizumab prior to initiating therapy. While our retrospective studies contribute 
to the literature, prospective research will be required to validate these approaches, as well as 
other  approaches  utilizing  other  advanced  imaging  techniques.  With  standardization  and 
validation,  these  advanced  imaging  techniques  can  ultimately  be  incorporated  into  everyday 
clinical use. Until these advanced techniques are better established, conventional MRI with two-
dimensional measurements as described by the RANO criteria remains the primary means of 
response assessment in bevacizumab-treated recurrent glioblastoma patients. Nonetheless, the 
continued  refinement  and  advancement  of  advanced  techniques  will  be  crucial  in  the  path 
towards  developing  reliable  imaging  biomarkers  that  can  be  ultimately  utilized  to  improve 
patient outcomes.  
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Figures 
 
Figure 1: Kaplan-Meier curves of subsequent survival by response in landmark analysis 
performed at 2, 4 and 6 months.   72 
 
 
Figure 2: Kaplan-Meier estimates of PFS as determined by RANO and Macdonald response 
assessment criteria. By log-rank testing, there was a small but significant difference in PFS 
(p=0.0423).  
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Duration, Months 
 Criteria           N              Median (95% CI)             
 Macdonald!   !N=163      5.52 (4.27, 6.83) 
months 
 RANO             N=163      4.21 (3.68, 5.49) 
months 
 logrank p-value=0.0423 73 
 
 
Figure 3: Kaplan-Meier curves of subsequent survival by progression in landmark analysis 
performed at 2, 4 and 6 months.   
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Figure 4*: Volume parameters of enhancing lesion. Kaplan-Meier estimates of overall survival 
(left column) and progression-free survival (right column) for different T1+C volume 
parameters. The patient sample was divided into two groups by dichotomizing by the median 
value for (A) baseline T1+C volume, (B) post-treatment T1+C volume, and (C) the percentage 
change of T1+C volume between those two scans. 
 
* Huang RY, Rahman R, Hamdan A, et al. Recurrent glioblastoma: Volumetric assessment and stratification of patient survival with early 
posttreatment magnetic resonance imaging in patients treated with bevacizumab. Cancer. 2013. doi:10.1002/cncr.28210. 
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Figure 5*: Combined stratifications using percentage volume change and post-treatment tumor 
volume.  
 
 
* Huang RY, Rahman R, Hamdan A, et al. Recurrent glioblastoma: Volumetric assessment and stratification of patient survival with early 
posttreatment magnetic resonance imaging in patients treated with bevacizumab. Cancer. 2013. doi:10.1002/cncr.28210. 
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Figure 6
#: Overview of tumor volume segmentation of T1+Contrast and nonenhancing 
T2/FLAIR hyperintensity.  Nonenhancing T2/FLAIR volume was generated by subtracting the 
T1+Contrast volume from the total volume of T2/FLAIR abnormality.  After co-registration, the 
T1+Contrast Volume and T2/FLAIR volume were mapped onto the ADC maps. The ADC 
values of individual pixels within the T1+C and T2/FLAIR volumes were then plotted into 
histograms.   
 
# Rahman R, Hamdan A, Zweifler R, Jiang H, Norden AD, Reardon DA, Mukundun S, Wen PY, Huang RY. ADC Histogram Analysis of 
Apparent Diffusion Coefficient within Enhancing and Nonenhancing Tumor Volumes in Recurrent Glioblastoma Patients Treated with 
Bevacizumab. Accepted for publication in the Journal of Neuro-Oncology.  
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Figure 7: Curve-fitting and area integrations were performed using peak center assignments 
based on previous reported ADC values. The peak parameters are specified as the following:  
ADCL (center < 1050 x10
-6mm
2/sec), ADCM (M1: center= 1150 x 10
-6mm
2/sec, width= 140 and 
M2: center=1350 x 10
-6mm
2/sec, width =140), ADCH (center = 1550 x 10
-6mm
2/sec).  The peaks 
were area-integrated and expressed as ratios, including %ADCL (=ADCL area / total area), 
%ADCH (=ADCH / total area), and ADCL  / ADCM (=ADCL area / ADCM area).  
 78 
 
 
 
Figure 8
#: Baseline ADC parameters. Kaplan-Meier estimates of overall survival (left column) 
and progression-free survival (right column) were calculated for the different ADC parameters. 
The patient sample was dichotomized by median value for (A) baseline %ADCH within T1+C, 
(B) baseline ADCL/ADCM within T2/FLAIR. In combining these two baseline ADC parameters, 
the patient sample was divided into 2 groups by dichotomizing by the optimized value of 0.8 for 
the (C) combined ADC factor. 
# Rahman R, Hamdan A, Zweifler R, Jiang H, Norden AD, Reardon DA, Mukundun S, Wen PY, Huang RY. ADC Histogram Analysis of 
Apparent Diffusion Coefficient within Enhancing and Nonenhancing Tumor Volumes in Recurrent Glioblastoma Patients Treated with 
Bevacizumab. Accepted for publication in the Journal of Neuro-Oncology.  79 
 
 
 
 
Figure 9: Combined stratification of the patient sample using the baseline enhancing tumor 
volume and combined ADC factor. 
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Tables 
Table 1: Patient characteristics from patients in the phase II BRAIN trial  
  % of Patients by Treatment Group 
Characteristic  Bevacizumab alone  Bevacizumab and irinotecan 
Sex     
Male  68.2  69.5 
Female  31.8  30.5 
     
Relapse     
First  81.2  80.5 
Second  18.8  19.5 
     
Initial surgery     
Partial resection  49.4  53.7 
Complete resection  42.4  37.8 
Biopsy only  8.2  8.5 
     
Enrollment relative to radiation     
< 3 months from completion of 
radiotherapy 
8.3  12.7 
> 3 months from completion of 
radiotherapy 
20.2  10.1 
 
   81 
 
Table 2: Spearman correlation coefficients correlating TTP 
  Other readers 
Macdonald PFS 
Other readers 
RANO PFS 
All readers RANO 
PFS  
-Primary reader 
Macdonald PFS  
0.688
a     
       
-Primary reader RANO 
PFS 
  0.692
a   
       
-All readers Macdonald 
PFS 
    0.781
b 
ap < 0.0001 (n=115) 
bp<0.0001 (n=278) 
   82 
 
Table 3*: Patient characteristics of institutional database  
  OS  PFS 
   
Hazard 
Ratio 
 
 
P-
value 
Median 
OS 
(weeks) 
 
Hazard 
Ratio 
 
 
P-
value 
Median 
PFS 
(weeks) 
Age (mean 56.3, range 23-
83) 
     <65 (n=69) 
     >65 (n=22) 
0.90  0.677   
38.7 
44.6 
0.67  0.117   
12.3 
20.0 
Gender 
     M (n=51) 
     F (n=40) 
1.36  0.210   
21.1 
28.7 
0.89  0.614   
13.7 
13.0 
Number of recurrences 
     1
st recurrence (n=47) 
     2
nd recurrence (n=29) 
     3
rd recurrence (n=11) 
     4
th recurrence (n=4) 
1.33 
 
0.036   
52.3 
32.0 
28.3 
35.6 
1.54  0.001   
20.3 
8.6 
12.0 
11.9 
Steroids at baseline (yes or 
no) 
    Steroids used (n=51) 
    Steroids not used (n=40) 
0.85  0.500   
39.0 
41.4 
0.68  0.089   
17.0 
12.7 
Change in steroid dose 
(from baseline to post-
treatment) 
     Increase (n=16) 
     Stable or decrease 
(n=75) 
0.92  <0.001   
 
21.1 
45.1 
2.77  0.001   
 
8.0 
14.9 
Bevacizumab treatment 
regimen 
     Monotherapy (n=47) 
     With concurrent     
     chemotherapy (n=44) 
1.37  0.188   
44.6 
38.7 
1.15  0.542   
14.9 
12.7 
Multifocal disease 
     Yes (n=12) 
     No (n=79) 
1.04  0.912   
38.7 
41.4 
0.78  0.467   
19.4 
13.0 
Time to bevacizumab 
initiation 
1.00  0.690    1.00  0.061   
 
 
* Huang RY, Rahman R, Hamdan A, et al. Recurrent glioblastoma: Volumetric assessment and stratification of patient survival with early 
posttreatment magnetic resonance imaging in patients treated with bevacizumab. Cancer. 2013. doi:10.1002/cncr.28210. 
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Table 4*: Volumetric parameters as continuous variables adjusted for clinical variables  
  OS    PFS   
  Hazard 
Ratio
a 
p-value
a    Hazard 
Ratio
a 
p-value
a   
Volumetric Parameters             
Baseline enhancing 
volume  
1.02  <0.001     1.01  0.037    
Post-treatment residual 
enhancing volume  
1.03  <0.001     1.03  <0.001    
Percent change in 
enhancing volume  
0.56  0.002     0.48  0.001    
Baseline FLAIR volume   1.00  0.15     1.00  0.57    
Post-treatment FLAIR 
volume  
1.01  0.025     1.01  0.018    
Percent change in FLAIR 
volume  
0.51  0.28     0.42  0.12    
Baseline rNTR   0.98  0.16     0.99  0.29    
Post-treatment rNTR   0.99  0.068     0.99  0.21   
aAdjusted for age, KPS, number of recurrences, re-resection before treatment (yes or no), 
baseline steroid dose, change in steroids (yes or no) and treatment regimen (bevacizumab 
monotherapy vs. concurrent chemotherapy) within Cox proportional hazards model  
 
 
* Huang RY, Rahman R, Hamdan A, et al. Recurrent glioblastoma: Volumetric assessment and stratification of patient survival with early 
posttreatment magnetic resonance imaging in patients treated with bevacizumab. Cancer. 2013. doi:10.1002/cncr.28210. 
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Table 5*: Multivariable analysis using Cox proportional hazards model  
  OS  PFS 
  
Hazard 
Ratio  p-value 
Hazard 
Ratio  p-value 
Age  (> or < 65)  2.30  0.088  0.58  0.21 
Baseline KPS  0.97  0.18  0.99  0.94 
Number of prior recurrences  1.54  0.062  1.65  <0.015 
Re-resection prior to bevacizumab treatment  0.86  0.75  0.85  0.66 
Baseline Steroid Dose  1.06  0.113  0.97  0.21 
Steroid dose change (stable/decrease vs. 
increase) 
1.29 
0.663 
2.4  0.065 
Regimen (monotherapy vs. concurrent 
chemotherapy) 
2.11 
0.048 
1.18  0.64 
Baseline enhancing tumor volume  1.02  0.041  0.99  0.75 
Post-treatment residual enhancing tumor 
volume  
1.03 
<0.001 
1.04  <0.001 
Post-treatment FLAIR  0.99  0.051  1.00  0.55 
  
 
 
* Huang RY, Rahman R, Hamdan A, et al. Recurrent glioblastoma: Volumetric assessment and stratification of patient survival with early 
posttreatment magnetic resonance imaging in patients treated with bevacizumab. Cancer. 2013. doi:10.1002/cncr.28210. 
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Table 6
#: ADC parameters as continuous variables adjusted for clinical variables 
   OS  PFS 
   
Hazard 
Ratio
a 
 
p-value
a 
 
Hazard 
Ratio
a 
 
p-value
a 
         
Baseline ADC Parameters         
%ADCL within T1+C  3.75  0.037
*  2.87  0.062 
%ADCL within T2/FLAIR  4.24  0.075  6.29  0.007
* 
%ADCH within T1+C  0.89  0.003
*  0.169  0.006
* 
%ADCH within T2/FLAIR  0.69  0.69  0.329  0.22 
ADCL / ADCM within T1+C  1.00  0.95  1.054  0.035 
ADCL / ADCM within 
T2/FLAIR 
1.23  0.014
*  1.19  0.008
* 
         
Post-Treatment ADC 
Parameters 
       
%ADCL within T1+C  9.89  0.009
*  7.032  0.010
* 
%ADCL within T2/FLAIR  4.27  0.093  5.919  0.022
* 
%ADCH within T1+C  0.19  0.085  1.731  0.029
* 
%ADCH within T2/FLAIR  0.65  0.75  0.444  0.032
* 
ADCL / ADCM within T1+C  1.01  0.71  1.016  0.41 
ADCL / ADCM within 
T2/FLAIR 
1.17  0.002
*  1.037  0.028
* 
         
Change before and after 
treatment 
       
%ADCL within T1+C  1.060  0.93  2.26  0.13 
%ADCL within T2/FLAIR  2.71  0.12  0.84  0.82 86 
 
%ADCH within T1+C  1.82  0.53  0.83  0.76 
%ADCH within T2/FLAIR  0.74  0.71  0.59  0.54 
ADCL / ADCM within T1+C  0.99  0.75  0.99  0.94 
ADCL / ADCM within 
T2/FLAIR 
1.10  0.07  1.03  0.18 
         
a Adjusted for age, KPS, number of recurrences, re-resection before treatment (yes or no), 
baseline steroid dose, change in steroids (yes or no) and treatment regimen (bevacizumab 
monotherapy vs. concurrent chemotherapy) within Cox proportional hazards model. 
* Significance level: p<0.05. 
# Rahman R, Hamdan A, Zweifler R, Jiang H, Norden AD, Reardon DA, Mukundun S, Wen PY, Huang RY. ADC Histogram Analysis of 
Apparent Diffusion Coefficient within Enhancing and Nonenhancing Tumor Volumes in Recurrent Glioblastoma Patients Treated with 
Bevacizumab. Accepted for publication in the Journal of Neuro-Oncology.  
   87 
 
Table 7
#: Multivariable analysis using Cox proportional hazards model  
  OS  PFS 
  Hazard 
Ratio 
p-value  Hazard 
Ratio 
p-value 
Age  1.067  0.002*  1.011  0.46 
Baseline KPS  0.984  0.48  1.014  0.39 
Number of prior recurrences  1.367  0.23  1.347  0.16 
Re-resection prior to bevacizumab treatment  1.443  0.54  1.151  0.77 
Baseline Steroid Dose  1.092  0.076  1.02  0.47 
Steroid dose change (stable/decrease vs. increase)  0.092  0.47  0.86  0.04* 
Regimen (monotherapy vs. concurrent 
chemotherapy)  1.418  0.42  0.911  0.795 
Baseline enhancing tumor volume  9.361  <0.001*  2.556  0.029* 
Baseline %ADCH within T1+C < or > 25%  0.341  0.012*  0.430  0.026* 
Post-treatment %ADCL within T1+C <= or > 
62%  1.90  0.19  1.962  0.071 
Baseline ADCL/ADCM within T2/FLAIR <= or > 
0.64  3.52  0.005*  2.822  0.02* 
Post-treatment ADCL/ADCM within T2/FLAIR 
<= or > 1.85  1.06  0.89  0.503  0.098 
 * Significance level: p<0.05. 
 
# Rahman R, Hamdan A, Zweifler R, Jiang H, Norden AD, Reardon DA, Mukundun S, Wen PY, Huang RY. ADC Histogram Analysis of 
Apparent Diffusion Coefficient within Enhancing and Nonenhancing Tumor Volumes in Recurrent Glioblastoma Patients Treated with 
Bevacizumab. Accepted for publication in the Journal of Neuro-Oncology.  
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Table 8
#: Median Overall Survival (days) stratified by baseline ADC parameters 
 
   
Baseline %ADCH within T1+C 
Baseline ADCL/ADCM  
within T2/FLAIR 
  < 25%  > 25%  p-value
*  <= 0.64  > 0.64  p-value
* 
Age             
<= 65 yr (n=69)  201  296  0.038  470  223  0.007 
> 65 yr  (n=22)  385  300  0.83  455  258  0.139 
             
Number of prior recurrences             
1 (n=47)  220  449  0.037  552  258  < 0.0001 
2 (n=29)  224  273  0.34  136  245  0.551 
>=3 (n=15)  309  198  0.25  198  223  0.499 
             
Treatment Regimen             
Bev Monotherapy (n=47)  141  300  0.007  455  245  0.013 
Concurrent therapy (n=42)  385  290  0.56  511  249  0.075 
             
Baseline enhancing tumor 
volume             
< 20 cm
3 (n=45)  385  455  0.09  511  336  0.045 
> 20 cm
3 (n=46)  141  223  0.025  273  182  0.012 
  
* Significance level: p<0.05. 
 
# Rahman R, Hamdan A, Zweifler R, Jiang H, Norden AD, Reardon DA, Mukundun S, Wen PY, Huang RY. ADC Histogram Analysis of 
Apparent Diffusion Coefficient within Enhancing and Nonenhancing Tumor Volumes in Recurrent Glioblastoma Patients Treated with 
Bevacizumab. Accepted for publication in the Journal of Neuro-Oncology.  
 